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Chapter 1
Summary
With the advent of high-throughput methods more genomic data then ever
has been generated during the past decade. As these technologies remain
cost intensive and not worthwhile for every research group, databases, such
as the The Cancer Genome Atlas (TCGA) and Firebrowse, emerged. While
these database enable the fast and free access to massive amounts of genomic
data, they also embody new challenges to the research community.
This study investigates methods to obtain, normalize and process genomic
data for computer aided decision making in the field of cancer subtype dis-
covery. A new software, termed FirebrowseR is introduced, allowing the
direct download of genomic data sets into the R programming environment.
To pre-process the obtained data, a set of methods is introduced, enabling
data type specific normalization. As a proof of principle, the Web-TCGA
software is created, enabling fast data analysis.
To explore cancer subtypes a statistical model, the Evolutionary Deci-
sion List (EDL), is introduced. The newly developed method is designed to
provide highly precise, yet interpretable models. The EDL is tested on well
established data sets, while its performance is compared to state of the art
machine learning algorithms. As a proof of principle, the EDL was run on
a cohort of 1,000 breast cancer patients, where it reliably re-identified the
known subtypes and automatically selected the corresponding maker genes,
by which the subtypes are defined.
In addition, novel patterns of alterations in well known maker genes
could be identified to distinguish primary and metastatic, castration-resistant
prostate cancer (mCRPC) samples. The findings suggest that mCRPC
is characterized through a unique amplification of the Androgen Receptor
(AR), while a significant fraction of primary samples is described by a loss of
heterozygosity Tumor Protein P53 (TP53 ) and Nuclear Receptor Corepres-
sor 1 (NCOR1 ).
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Chapter 2
Introduction
One of the first studies which combined bio-medical feature engineering, ma-
chine learning and cancer classification was published by Street, Wolberg
and Mangasarian back in 1992/1995 [122, 82]. In their work Street et al
digitized images of 569 Fine-needle aspirations (FNAs), 357 obtained from
benign tissue, 212 from malignant tissue. Using a computer aided approach,
pathologists determined ten features (shape, radius, density, etc.) for each
cell. For each feature they calculated its mean, maximum and standard de-
viation (SD). Using these 30 features a predictive linear model for tissue
detection with an accuracy of 97% could be generated. This model is shown
in figure 2.1 and depicts the separating hyperplane for both tissue types,
based on three manually selected features. With this simple, yet power-
ful approach Street et al laid the foundations for predictive modelling in the
field of cancer-biology. During the past 25 years much has changed, while the
foundations remain identical. Still, medical and biological data is digitized.
Based on that, predictive modelling, feature selecting or outlier discovery is
applied. While this workflow remains intact, new technologies emerged, es-
tablished technologies became more sophisticated and affordable. Nowadays
an individuals genome can be characterized on several levels, whether it is
the detection of mutations to the genome or the measurement of the genes’
activity. Additionally, these information are made publicly available over the
internet, adding value to the scientific community. While the amount of data,
whether is self generated or obtained over the network, increased drastically
and investigated issues became more and more complex, new methods for
data processing and analyses are needed.
This study investigates methods to share, process and analyse state of
the art genomic data by the means of predictive modelling, with the aim of
cancer subtype classification.
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Figure 2.1: Based on the three features (area, smoothness and texture), a
hyperplane separates benign from malignant tissue. Figure adapted from
Street et al [122].
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Table 2.1: The three marker genes which are used to define breast cancer
subtypes. Table compiled from St. Gallen Criteria Catalog [51].
Subtype Clinico-pathological definition Therapy
Luminal A ER+ and/or PgR+, Her2- Endocrine therapy
Luminal B ER+ and/or PgR+, Her2-/+ Endocrine therapy + Chemo therapy (+ Anti Her2 therapy)
Her2 ER- and/or PgR-, Her2+ Chemo therapy + Anti Her2 therapy
Basal-like ER-, PgR-, Her2- Chemo therapy
normal-like No unique pattern Endocrine therapy + Chemo therapy
2.1 Breast Cancer & Subtypes
With 246,660 new cases every year in the United States (US) alone, breast
cancer is the most common cancer affecting 29% of all female cancer pa-
tients [116] (a short summary of cancer statistic is given in figure 2.3). While
the term “breast cancer“ is synonym with a tumor to the mammary gland,
the diseases characterizes through a heterogeneous profile of molecular alter-
ations, cellular composition, and clinical outcome, allowing a classification
into distinct subtypes. Despite from intuitive markers like tumor size, lymph
node status, age, grade, three molecular markers are considered. Namely
Estrogen Receptor 1 (ESR1 ), Progesterone Receptor (PgR) and Erb-B2 Re-
ceptor Tyrosine Kinase 2 (ERBB2) [57, 22]. The status of these markers is
used to define the molecular subtypes, namely Luminal A, Luminal B, Basal-
like, Her2 and normal-like. An overview which pattern of activation results in
which subtype is given in table 2.1, where +/- indicate whether a gene is found
positive (overexpressed) or negative (underexpressed). It is to say, that the
criteria given in the table are based on observations, which are found to be
statistically relevant. Hence, these patterns are observed frequently, but do
not represent every single sample. These groups were initially identified by
Perou et al [100]. Several years later, Parker et al [96] provided relapse-free
survival estimates for each of the subtypes. As shown in figure 2.2, tumors
with an enrichment of Her2 show the worst outcome, while Luminal B and
Basal-like tumors show a slightly better prognosis. The best prognosis for
relapse free survival has the Luminal A subtype. Additionally, Parker et all
identified 50 genes, by which patterns of expression a more precise sample to
subtype assignment could be achieved. This list of genes is called Prediction
Analysis of Microarray (PAM) 50 and was the starting point for molecular
subtyping of breast and other cancer entities. Based on these findings, sev-
eral other studies emerged over the past years, identifying relations between
mutations, Copy Number Variations (CNV) and the gene expression status
[92, 2, 27]. Hence, the identification of ERB2 as potential target for Her2+
patients, the expression of Cyclin B1 (CCNB1 ) as marker to distinguish Lu-
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Prognostic and Predictive Models Using Clinical and
Molecular Subtype Data
Univariate and multivariable analyses were used to determine the
significance of the intrinsic subtypes (LumA, LumB, HER2-enriched, and
basal-like) in untreated patients and in patients receiving neoadjuvant chem-
otherapy. For prognosis, subtypes were compared with standard clinical vari-
ables (tumor size [T], node status [N], ER status, and histologic grade), with
time to relapse (ie, any event) as the end point. Subtypes were compared with
grade and molecular markers (ER, progesterone receptor [PR], HER2) for
prediction in the neoadjuvant setting because pathologic staging is not appli-
cable. Likelihood ratio tests were done to comparemodels of available clinical
data, subtype data, and combined clinical and molecular variables. Categoric
survival analyses were performed using a log-rank test and visualized with
Kaplan-Meier plots.
Developing Risk Models With Clinical and Molecular Data
The subtype risk model was trained with a multivariable Cox model
using Ridge regression fit to the node-negative, untreated subset of the van de
Vijver cohort.13ARORscorewasassigned toeach test caseusingcorrelation to
the subtype alone (1) (ROR-S) or using subtype correlation alongwith tumor
size (2) (ROR-C):
ROR-S ! 0.05 ! basal " 0.12 ! HER2 "
#0.34 ! LumA " 0.23 ! LumB (1)
ROR-C ! 0.05 ! basal " 0.11 ! HER2 "
#0.23 ! LumA " 0.09 ! LumB " 0.17 ! T (2)
The sum of the coefficients from the Cox model is the ROR score for each
patient. To classify samples into specific risk groups,we chose thresholds from
the training set that requirednoLumAsample tobe in thehigh-risk groupand
no basal-like sample to be in the low-risk group. Thresholds were determined
from the training set and remained unchanged when evaluating test cases.
SiZeranalysiswasperformedtocharacterize the relationshipbetween theROR
score and relapse-free survival26 (Appendix FigA4, online only). The 95%CIs
for theROR score are local versions of binomial CIs, with the local sample size
computed from a Gaussian kernel density estimator based on the Sheather-
Jones choice of windowwidth.27
Comparison of Relapse Prediction Models
Four models were compared for prediction of relapse: (1) a model of
clinical variables alone (tumor size, grade, and ER status), (2) ROR-S, (3)
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Figure 2.2: Kaplan-Meier plot for each breast cancer subtype defined by
Parker et al, showing the relapse free survival probability. Figure adapted
from Parker et al [96].
minal A from Luminal B samples and the Luminal A specific mutations in
GATA Binding Protein 3 (GATA3 ), Phosphatidylinositol-4,5-Bisphosphate
3-Kinase Catalytic Subunit Alpha (PIK3CA) and Mitogen-Activated Protein
Kinase Kinase Kinase 1 (MAP3K1 ) [15, 14, 77, 50].
Compared to other cancer entities, such as prostate cancer, the molecular,
transcriptomic and genomic profiles of breast cancer are understood relatively
well. The initially identified subtypes for breast cancer could be validated in-
dependently by other research groups [27, 93]. Additionally, more and more
knowledge regarding each subtype was generated, which let to the identifica-
tion of additional marker g nes, influencing the genomic and transcriptomic
machinery and yieldidingg the development of a specific subtype. Also, in
the light of disease treatment, the identification of potential therapeutic tar-
gets became a major advantage, as the treatment can happen person lized.
These findings led to the current state of the art therapy forms, showing less
side effects and afflictions.
In this study, breast cancer and its corresponding subtype ar used for
model evaluation. The newly developed EDL model will be tested, despit
from other data sets, on breast cancer data, with the aim to re-identify its
subtypes and marker genes. Therefore, breast cancer data is used to provide
a proof of principle, before the model is evaluated on prostate cancer.
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Figure 2.3: An overview of detected cancer cases in the US in the year 2013.
Most prominent are breast and prostate cancer, for female or male patients.
Figure adapted from Siegel et al [115].
2.2 Prostate Cancer
With one quarter, 180,890, of all detected cancer cases, prostate cancer is
the most common cancer in the male population [115] (US alone). While
breast cancer is the most common cancer in woman, which is rarely detected
in men, prostate cancer is specific to men (for a ratio overview see figure
2.3). As the primary disease is asymptomatic in its early stage and unlike to
cause complaints, prostate cancer is often detected in an advanced stage only.
Often, in this advanced stage, metastasis have already formed in the lymph
nodes and/or bone, lowering the chances of cure drastically [125]. As prostate
cancer, in its early stage, does not cause any symptoms, it remains hard to
detect. Therefore medical check-ups are offered to men of age 50 and older.
During these check-ups the prostate is examined by touch, ultrasound and/or
prostate-specific antigen (PSA) screening. While the touch examination is
likely to miss tumors located at the organs front, the ultrasound examination
is only capable of detecting tumors of size 10 millimeter (mm) or bigger, while
smaller tumors are only detected with a probability of 20% [71]. For PSA
screening, the concentration of PSA within the blood is determined. While
the level of concentration is intended to be used as an indicator for prostate
cancer, there exits no coherent approach for examination, as the PSA level
varies vastly from individual to individual [58]. As a consequence, a high
PSA level could be an indicator of prostate cancer or just be an artefact,
brought about urinary retention or infection [83, 21]. While the medical
check-up is just capable of detecting a primary tumor to the prostate, not
yielding any information about its state, it remains unclear how the tumor
will develop. While a primary tumor, detected at an old age, may be just
observed without any therapy (watchful waiting), other tumors tend to be
very aggressive. These aggressive tumors yield a lethal disease progress and
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are known as mCRPC, as they do not show any reaction to the reduction
of male sex hormones through castration or drug usage [55]. While the
treatment of an early stage tumor is simple and promising, treatment of
mCRPC remains an ongoing challenge [44, 43, 30].
Therefore, the identification of genomic, transcriptomic or molecular mark-
ers for the early detection and classification of prostate cancer is a crucial
task, as current risk stratification systems do not provide sufficient results
[24, 28, 67]. Recently, just as for breast cancer, several studies revealed corre-
lations between genomic alterations, copy number changes and the expected
disease outcome [133, 128, 125, 101, 3]. The most frequent alteration to the
genome, found in 40-50% of all samples, is a gene fusion of Transmembrane
Protease, Serine 2 (TMPRSS2 ) and ERG, ETS Transcription Factor (ERG)
[97, 129]. Nevertheless, the occurrence of this alteration does not seem to
influence metastatic formation [93]. On the other hand side, there exists
a wide variety of structural alterations such CNV, single nucleotide variant
(SNP) and other copy number changes, which are observed in mCRPC, but
not in primary prostate cancer [93, 107]. Highlighting the need for early
stage development markers.
2.3 Modelling & Understanding Omics Data
The term omics functions as a proxy for proteomics, genomics and transcrip-
tomics and describes, in the context of this study, the pooled data types. The
term has been around since the breakthrough of high-throughput technolo-
gies. These high-throughput technologies transformed biology and medicine
from a relative data poor discipline, into a field where massive amounts of
data are generated on a daily basis. This let to several problems, ranging from
the initial batch effect corrections, over the primary analyses, up to storage
and distribution of these large files [64]. Not only, that this data needs to be
stored, it also has to undergo a pipeline of processing steps to generate use-
ful information. This complete processing pipeline is based in assumptions,
approximations and models. Starting with the sequencing machine, which
digitizes deoxyribonucleic acid (DNA) sequences based on colored cells by
photography, over the mapping algorithm, which aligns reads to the most
promising position in a reference genome (which is also just an approxima-
tion [110]) or the statistical model, trying to infer which alterations lead
which disease type.
It is obvious that each step of this processing embodies an area of studies
on its one. Therefore, at a certain point, the given information have be
accepted as gold standard, on which basis additional studies can be build
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upon. With TCGA the National Cancer Institute (NCI) and the National
Human Genome Research Institute (NHGRI) booted a project to improve
the ability to prevent cancer through a better understanding of the genetic
basis of this disease, based on high-throughput genome analysis techniques.
The TCGA collects data sets from several research projects of their partner
institutions and provides the aggregated cohorts to the research community.
It is ensured that the data is accessible to any researcher world wide, offering
a whole new resource to scientists. While over the past decades the access to
large cohorts required the seizure of pathological archives, high-throughput
facilities and an interdisciplinary team, these cohorts can be accessed simply
over the network.
Not only that this led to a better understanding of the diseases, it also
yielded new and more sophisticated methods, which would not have been
developed without such projects [87, 114, 140, 27]. A major role in this area
is taken by machine learning or statistical modelling, where, under certain
framework conditions, a model is fitted to data. The model is then used to
infer and uncover additional information about the data, which are not obvi-
ous at the first glance. This attempt can be used to address a wide variety of
issues. For example, models might be used to make predictions, to identify
pattern in data or to unveil groups of samples. Each time a model is fitted,
its eventual purpose should be known and declared upfront. Hence, it seems
obvious that complex models1 are capable of fitting complex relations in data,
while more simple models can only fit aspects to a certain degree. Examples
for both ends might be a neural network and a linear regression model. While
the neural network is capable to even decipher complex structures within the
data (hand writing recognition [72], for example), the linear regression model
simply estimates two parameters, estimate and slope, not allowing such a de-
tailed classification. While complex models seem superior at the first glance,
they have an essential drawback, which is often overseen beforehand. Inter-
pretability. As these complex models might be able to fit the data almost
perfectly, they remain nearly impossible to infer and interpret. Vice versa,
simple models might not gain competitive, yet acceptable performance, while
unveiling true relations within the data to the user. Therefore, a trade-off be-
tween complexity, precision and interpretability should be found, allowing a
precise classification while remaining interpretable. This way true coherences
within groups of data can be identified.
1For simplicity, models with more parameters and degrees of freedom.
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2.4 Aims of the Study
Certain cancer entities can be subdivided into several subtypes, where each
of those subtypes shows a different life expectancy and therapy response.
While such classifications used to be based on symptoms, phenotypes and
progression, they are now investigated by alterations on the molecular level.
For some cancer entities patterns of alterations could be identified, enabling
an assignment for a single sample to one of the known subtypes. One of those
cancer entities is breast cancer, where, depending on the identified pattern,
a therapy is chosen. For prostate cancer, the course of disease shows two
extremes. First, patients do not require any therapy, living a complaint free
live. Second, the tumor forms metastasis, afflicting the bones and lymph
node system. To identify novel driving alterations, leading to one of such
extremes is the goal of this work.
This goal can be partitioned into three tasks,
1. the aggregation of omics data sets, enabling investigations on the ge-
nomic, transcriptomic and molecular level,
2. the normalization and representation of these data sets, such that they
are can be inspected by a statistical model and
3. the development of a human interpretable statistical model, allowing a
precise subtype assignment.
2.5 Pre-Published Results
Parts of this thesis have already been published in peer-reviewed international
scientific journals. All paragraphs, graphics, tables, etc., where this is the
case, are cited as appropriate. In addition an overview is given at this place.
• Section 3.5, including figures 3.4 and 3.5, see [31]. Database - The
Journal of Biological Databases and Curation. IF: 2.627
• Section 4.2, including figures 4.5, 4.6 and 4.7, see [32]. BMC Bioinfor-
matics. IF: 2.435
• Section 4.2, including figures 4.5, 4.6 and 4.7, has been presented at the
useR2016, the official conference for the R programming environment,
at the Stanford University.
Chapter 3
Materials & Methods
In this chapter the computing environment and used software tools are in-
troduced. As the newly developed model, EDL, has to undergo performance
tests, four test data sets are introduced for benchmarking in 3.2. As the
eventual analyses of cancer subtypes is based an alterations of the human
genome, all inspected types of alterations are introduced in 3.3. Databases,
from which the cohorts for analysis are obtained, are introduced in 3.4. Re-
quired pre-processing steps the data has to undergo before analyses are then
discussed in 3.5. Afterwards basic concepts machine learning are introduced
and established machine learning methods are presented 3.6, which are used
for performance comparison. Finally, the newly designed classifier is in-
troduced in 3.7 along with the corresponding metrics, allowing a reliable
comparison between the newly developed classifier and established models
3.8.
3.1 Computing Environment
All calculations produced in the context of this study are carried out by the
R Programming Environment, version 3.3.2 - Sincere Pumpkin Patch. R is
an open source programming language and software environment, provided
by the R Foundation for Statistical Computing [105], offering a wide va-
riety of extensions for statistical modelling, plotting and high performance
computing. Besides the functions provided within the R core distribution,
additional packages have been used. For plotting, Hadley Wickhams gg-
plot2 [136] library (version 2.2.1) has been utilized and C++ (version 11)
extensions have been coupled to R by using Dirk Eddelbuettels and Romain
Francois’ Rcpp extension [38] version (0.12.8), while Apple LLVM (version
800.0.42.1) has been used for compilation. Transfering calculations from the
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R to the C++ environment drastically enhances the computing performance,
as the source code is translated to byte code first. While the execution of R
source code is done one a higher level, leaving type declarations undefined
until computation. For more details, the reader is referred to Eddelbuettels
Rcpp integration guide [37]. Other packages used for statistical modelling
etc. are cited at the appropriate position.
3.2 Test Data Sets
As one task of this work is the development of a statistical classifier, test
data sets are required to determine the models performance in comparison
to already established models. For this task, four well known data sets have
been chosen. The choice of those data sets has been made with regard to
the final tasks of feature selection and decision making for cancer subtypes.
Therefore, all test sets have identical quantities of instances and predictor
variables, compared to the cancer data sets, allowing an approximation of
the inter-rater reliability for cancer models. Also, non of the data sets chosen
is trivial, that is that the label can be determined by a single predictor.
The Tic Tac Toe data encodes all possible board configurations (958) of
the Tic Tac Toe game. Each configuration is represented by a combination
of the nine fields, where each field can take the values x, o and b, indicating
if the filed is taken by a player or blank (b). The label to predict is TRUE
or FALSE, encoding if player x has won or not.
The Titanic data compiled by the British Government [53] provides in-
formation on the fate of passengers who traveled on the first and only voyage
of the Titanic ocean liner. Recorded parameters are class, sex and age, where
the label to predict is the survival. Overall 2,201 records exist, which are part
of the R core package.
The Mushrooms data represents 8,124 different mushrooms by 22 at-
tributes. The label to predict is if a mushroom is whether edible or poisonous.
Unknown or not recommended edibility has been as encoded as poisonous as
well. The data is extracted from National Audubon Society Field Guide to
North American Mushrooms [120].
The Cars database was generated by Vladislav and Bohanec [8] in 1988
and represents a decision model, that predicts the acceptability of a car
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by the customers. The label to predict can take the four values of unac-
cepted (“unacc“), accepted (“acc“), good acception (“good“) and very good
acception (“vgood“), denoting the cars market acceptability. Each car is
described by six attributes: buying prices (“buying“), maintenance effort
(“maint“), number of doors (“doors“), numbers of seats (“persons“), storage
space (“lug boot“) and “safety“.
The introduced data sets serve as an ideal foundation to test a newly
developed classifier for cancer subtype discovery. That is, all data sets have
at least as many records as the assembled cohorts, also they come with an
identical amount of attributes. Further, the Cars and Mushrooms data sets
harbour a mixture of continuous, categorical and binary attributes, which is
also the case for the cancer data sets.
3.3 Genomic Events
The foundations for carcinogenesis and cancer progression are alterations to
the cascade of transcription and translation. Small changes to the DNA,
mostly caused by environmental factors, effect the organisms and disrupt
the cell cycle. While some alterations result in the dysfunctionality of tumor
suppressor genes, others promote the hyperfunction of oncogenes, which has
the potential to cause cancer. These malfunctions are caused by a wide
variety of alterations to the genome. In the following an introduction of the
investigated alterations in this study is given.
3.3.1 Single Nucleotide Polymorphisms, Insertions &
Deletions
Next Generation Sequencing (NGS) has enabled the study of the complete
human genome, exome and transcriptiome, unlike earlier methods, which
only allowed the study of selected areas of an organisms’ genotype. Next
generation sequencing led to an exponential growth of sequencing productiv-
ity, resulting in fast and cheap ways to analyze DNA sequences. Regardless
of the underlying sequencing technology, the basic workflow for analysing
NGS data remains identical, as each sequencing facility provides reads as
output. i) An alignment is performed, where short reads are arranged to the
most identical part of a reference genome [52]. ii) Mutations, such as SNPs
(see figure 3.1 A) and insertions/deletions (INDELs), between the aligned
reads and the reference genome are identified. Mutations may affect the
translation, causing a malformed or dysfunctional protein. Affected tumor
suppressor genes, can not fulfil their initial function anymore, often resulting
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Figure 3.1: Overview of structural variants occurring A) single nucleotide
polymorphism B) deletion of a complete gene C) partial inversion of gene
sequence D) copy number variation / multiple copies are present E) dupli-
cation of a segment of multiple genes. Figure adapted from Mullally & Ritz
[90]
in an individuals cancer disease. Further, patterns of mutations and mutated
genes form footprints, which are specific to certain cancer types. For exam-
ple, mutations effecting GATA3 , PIK3CA and MAP3K1 are unique to the
Lumal A breast cancer subtype [92]. Also, mutations and the genes they are
effecting, can serve as potential therapeutical target, as the knockdown of an
oncogene may recover the initial cell cycle.
3.3.2 Copy Number Variation & Gene Fusions
A CNV, along with SNPs and INDELs, is another known structural vari-
ant. A structural variant is classified as CNV, if its affecting more than 50
base pairs (bp) or covers complete genes (definition adapted from Zarrei et al
[143]). Regularly each gene occurs exactly two times within the individuals
genome. That is one copy per chromosome set. A CNV has taken place if
i) one (heterozygous) or both (homozygous) of its copies are deleted (figure
3.1 B) or ii) a single gene (gain, figure 3.1 D) or a sequence of genes oc-
curs multiple times (high level amplification, figure 3.1 E). As with SNPs
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and INDELs, CNVs can have phenotypic effects on the organism. While
an increase of copie numbers can result in an increased amount of protein,
heterozygous and homozygous deletions can result in a decreased or total
absence of protein.
Another event is the gene fusion, which leads to a new gene out of two
previously separated ones. This event can take place if i) two chromosomes
are translocated, ii) a segment of the whole chromosome (and not only the
gene) is deleted and iii) the chromosomes inversion. Generally, this takes
place if two parts of two genes are arranged next to each other and the
resulting amino acid sequences lays in between a promoter region and stop
codon. Often the resulting product can produce a more active abnormal
protein, causing tumor formation [39]. In the case of prostate cancer, > 50%
of patients showing a overexpression of the oncogenes ETS Variant 1 (ETV1 )
and ERG , a gene fusion between one of the genes and TMPRSS2 can be
found [129].
3.3.3 Gene Expression
While NGS, CNV and fusion analysis provide an organisms footprint on
the lowest level, the genotype, the gene expression analyses determines how
the genotype is expressed into its final form, the phenotype. While older
methods, such as gene expression chips, required a target for each gene on the
chip, newly established methods make use of NGS. Here the Ribonucleic acid
(RNA) is sequenced and aligned to the reference, afterwards the frequency
of reads which bound to a certain transcript is determined. The final gene
expression can then be determined by the genes transcripts expression. To
fulfil this task, a wide variety of approaches exits. An overview is provided
by Teng et al [35]. The foundation of gene expression is made on genomic
level, where influences derived from CNVs, SNPs or INDELs can have an
effect on how a gene is regulated and expressed into its protein. The gene
expression analyses is the consequential next step after sequence analysis, as
the latter describes the building blocks and the former the building blocks
final product.
3.4 Databases
The exponential growth of sequencing data, affordable IT infrastructure and
the revolution of noSQL technologies lead to a new type of databases. Not
that the underlying technology would have changed, furthermore it is now
possible to setup, maintain and scale large public databases, with a minimum
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of cost [89].
3.4.1 The Cancer Genome Atlas
In the field of cancer research, TCGA has been the first of such databases.
Since its launch in 2005 [135], TCGA has become the biggest portal, making
large scale omics data publicly available. With the aim to improve diag-
noses, treatment, and prevention of cancer through a better understanding
of the disease genetics, TCGA applies high-throughput genome analysis to
comparative large cohorts. At time of writing TCGA stores 15,000 cases,
distributing over 29 cancer entities. While TCGA processes genomic data
only to a certain level, it serves as an input for other data portals, which set
up their analyses pipeline on top of TCGAs.
3.4.2 Firehose Pipeline
The Broad Institute’s Firehose Pipeline is one of the projects which post-
processes TCGA output. It is born out of the desire to systematize analyses
based on data obtained from TCGA and scale the execution of pipelines for
new data to come. Thereby it processes 55 terabytes of data every month,
re-running each pipeline for updated data sets. While TCGA provides rudi-
mentary results only, Firehose integrates the output from plenty of (de facto)
standard tools (figure 3.2). To distribute the generated output and to make
it available to the end user, the Broad Institute provides a facility called
Firebrowse. Firebrowse serves as a gateway to the analytical results. Using
it, researchers can collect data in a convenient way over a web interface. Ad-
ditionally, Firebrowse also holds an application programming interface (API)
available. This way, users can automate their processing pipelines without
the need of manual adjustment. As partial results of this thesis, an R client
to the Firebrowse API is presented in section 3.5.
3.4.3 cBioPortal
As depicted in figure 3.2 another post-processing tool, named cBioPortal,
obtains its input from TCGA and Firebrowse. The cBioPortal has been
published in 2012 by Cerami et al [16], describing it as portal for “visu-
alization, analysis and download of large-scale cancer genomics data sets“.
Compared to the TCGA and the Firehose Pipeline, cBioPortal offers inter-
active tools, which do not only allow the download of genomic data, but also
the direct analyses. Using cBioPortal one can design and directly investigate
the aggregated cohorts, in terms of mutations, copy number variations and
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Figure 3.2: The information flow for TCGA, Firehose Pipeline and cBio-
Portal. It should be noted that Firehose is fed by the TCGA only, while
cBioPortal also obtains data from other resources, which is not depicted in
this illustration. Figure adapted from The Cancer Genome Atlas Research
Network et al [134].
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Figure 3.3: Schematic workflow of the cBioPortal: Data is collected from
different studies or cohorts and the shown data types are harmonized and
analyzed to be accessed by the user. Figure adapted from Cerami et al [16].
many more. Figure 3.3 depicts the available data types. Another unique
characteristic is the integration of data which is not derived from TCGA
/ Firehose Pipeline only. cBioPortal also includes data sets and published
findings from larger studies, offering an easy way of reproduction, serving as
building block for own investigations. Data from both portals has been used
in this thesis. For information on how the cohorts have been assembled, the
reader is referred to 4.4.1, while the process of data integration is outlined
in 3.5.
3.5 Data Integration
To integrate data into the R programming environment an R client to the
Firebrowse Representational State Transfer (REST) API has been imple-
mented. This client provides several benefits over manual downloads, as
updates to the data can be obtained easily, changes to the database do not
effect the data processing pipeline and let the developer focus on his task. As,
during time of its development, the API was prone to changes and updates1, a
workflow to automatically update, test and deploy changes to the API client
has been developed. The workflow decouples changes on the server side from
the client, as it automatically updates the client based on changes to the
servers REST interface. This workflow is utilized to provide FirebrowseR,
an R client to the Broad Institute’s Firehose Pipeline (for more details the
reader is referred to Deng et al [31]). As the source code is made publicly
available2 and transparent, both, the workflow and its deployed software
product, FirebrowseR, are actively used in-house, but also by the research
community. Finally, FirebrowseR became the Broad Institute’s official R
1The first public beta was launched on 23rd April, 2015 and left its beta status on 2nd
March, 2016.
2FirebrowseR’s source code repository can be found under https://github.com/
mariodeng/FirebrowseR.
3.5. DATA INTEGRATION 21
client3.
Once the data is made available to the programming environment, addi-
tional steps for data normalization need to take place. As working with data
sets obtained from TCGA and the Firehose Pipeline took a central part of
this study, the Web-TCGA application has been created and published by
Deng et al [32]. Web-TCGA in a graphical front end to Firehose Pipeline,
enabling users to quickly inspect cohorts and obtain a brief summary. As
the pre-processing methods required by Web-TCGA are identical to those in
this study, the methods implemented by the Web-TCGA software form the
foundation for data integration and normalization.
3.5.1 Background
To share information is a common task in the field of cancer research. The
method of file transfer and chosen file type often strongly depend on the
providers infrastructure. Data sets of low complexity are often organized
as Comma Separated Values (CSV) files, as done with Variant Call Format
(VCF) (see Danecek et al [29] for details on the format), or just stored
as plain text file, as done with Sequence Alignment Map (SAM) format
described by Li et al [80]. An alternative for storing information is provided
by Database Management System (DBMS), where information is persisted
in a structured way. It is the structure that reduces the data overhead when
DBMS are used, as each entry is only persisted once and other occurrences
are linked to that entry. Both of these methods mark an extreme at each
end. While storing data in the CSV format means easy input and output to
programming environment, it comes with a massive overhead of storage, as
redundant information are persisted. Data stored using DBMS reduces this
overhead, but makes data integration and modelling a bit of task. Further, it
is almost impossible to receive or provide data to a DBMS if its structure is
unknown. Also, the user needs to take updates to database or CSV structure
into account, denoting a potential weak spot in the analyses pipeline.
One way to overcome these obstacles is the use of an RESTful API. While
the API is the interface to an application, REST provides a framework for
how the machine-machine interaction is realized. This machine-machine in-
teraction is commonly realized over Hypertext Transfer Protocol (HTTP)
verbs, defined by Berners-Lee and Fielding back in 1996 [7, 42]. If the data
transport is encapsulated through an RESTful API, changes made to the
database will not effect the communication, as the API remains stable. Also
3See press release: https://confluence.broadinstitute.org/display/GDAC/
FireBrowse+Release+Notes.
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Figure 3.4: The root entry of the Firebrowse API, providing meta infor-
mation, as well as sub-APIs, which can be traversed to unfold all functions
provided by the API. Figure adapted from Deng et al [31].
the underlying structure of the database is completely decoupled from the
communication. This allows the implementations of more advanced methods,
which will not affect the usability. Applications, such as Firebrowse, real-
ize their communication over Uniform Resource Locator (URL) queries and
deliver results in a structured format, such as JavaScript Object Notation
(JSON) or CSV. If the API itself receives an update, its definition changes
and the client software can automatically adapt the new definition, as it is
public available.
3.5.2 Implementation
The benefit of using an API over other technologies is, that the its definition
is made available through the API itself. Hence, it can be reached from any
computing environment over the network. This definition is structured in a
hierachical fashion, starting from the entry point, the root. For Firebrowse,
this root can be found by the following URL http://firebrowse.org/api/
api-docs/. For convenience this definition is also depicted in figure 3.4.
At the top level, three entries can be found i) “apiVersion“, ii) “apis“ and
iii) “swaggerVersion“, where i) and iii) are meta information, by the software
used to generate this definition. Traversing the “apis“ entry, all definitions of
the API and its functions can be found. These entries provide the developer
with information needed to communicate with the API, such as methods
names, parameter data types and HTTP verbs used for interaction. Out of
these definitions, almost all code required to build a client software can be
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generated. Therefore, a blank template for R functions is created, which
is completed with the information obtained from the APIs definition. For
template creation Rs mustache4 implementation whisker5 is utilized. The
template is designed in a way, that for each function provided by the API a
corresponding R function is created. This function, again, interacts with cen-
tralized download manager. This has the benefit that no code is duplicated
and the number of potential sites of fractures can be reduced to a minimum.
Now, to combine definitions and the templates, the API is traversed and for
each definition a template is completed.
3.5.3 Workflow & Usage
The complete workflow is a combination of free and publicly available web-
services and depicted in figure 3.5. A cron-job6 checks if a new API version is
available. If so, the new versions source is build using the whisker templates
and the new API definitions. Afterwards the new code is pushed to develop-
ment branch on GitHub. The code is then tested by Travis-CI with upfront
written unit tests. If an error occurs, the developer is notified, otherwise
a new release is finalized by pushing the code to the master branch. The
FirebrowseR package is publicly available on GitHub (master branch) and
can be installed and used by anybody. After installation, data provided by
Firebrowse can be downloaded directly into the R environment. Further the
user can chose whether to use matrix or JSON objects, allowing maximum
flexibility.
3.5.4 Data Normalization
Data obtained from the Firehose Pipeline is already processed to a cer-
tain level, reducing the workload for pre-processing. Nonetheless, some pre-
processing is still required with regard to the follow-up analyses. All methods
used for pre-processing and normalization are discussed on the example of
Web-TCGA, an online platform for integrated analysis of molecular cancer
data sets by Deng et al [32]. Web-TCGA has been developed as a side project
of this thesis, highlighting the normalization, usage and depiction of data ob-
tained from the Firehose Pipeline. While the first version of Web-TCGA re-
quired manual data download, the new version7 utilizes FirebrowseR, making
manual downloads redundant. That is possible, as both software packages
4See https://mustache.github.io/ for details.
5Whisker is available via GitHub https://github.com/edwindj/whisker.
6The cron-job is hosted on https://cron-job.org/.
7Currently under development.
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Figure 3.5: The complete workflow which is run to build a new version
of FirebrowseR. The cron-job service checks for new API definitions and
generates the source code for the new version, if necessary. The source code
is then checked by Travis-CI and pushed to the repositories master, if not
errors occur. Figure adapted from Deng et al [31].
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are written in the R environment. Further, by utilizing FirebrowseR, Web-
TCGAs data repository is always synchronized with the latest version from
Firehose Pipeline.
Within TCGA the data are provided on different levels. Levels range
from one to three, indicating an increasing state of pre-processing and data
aggregation each. Raw-data only is provided on level one, the second level
is characterized by canonical pre-processing or filtering (depending on the
data type, see below). The third level provides data which is appropriate for
analyses.
To reduce calculation time and to keep the amount of data as small as
possible, data used in this study and by Web-TCGA always includes the
highest data level available for each type. Somatic mutation data (level 2)
and somatic CNV data (level 3, GISTIC2.0 output [86]) is directly used,
as it dies not require any further processing. For gene expression profiling,
level 3 data is imported by FirebrowseR and processed as described below.
For the expression status, two different preprocessing methods are available,
namely RNA-SeqV1 (Reads Per Kilobase per Million (RPKM)) and RNA-
SeqV2 (RNA-Seq by Expectation Maximization (RSEM)). Here, RNA-SeqV2
is used, which takes transcript length into account and is found to provide
more accurate results [79] for downstream analysis. For RNA-SeqV2, gene
expression profiles are calculated using RSEM data. Due to the lack of
normal samples, the relative expression for a specific gene is calculated using
its expression status in a tumor sample of a given entity, compared to its
average expression status in the remaining samples of the same entity [94].
The degree of differential expression is calculated using the z-score. The z-
score is defined as number of standard deviations above or below the mean
of the gene’s expression levels in the reference cohort.
Z =
X − µ
σ
, (3.1)
where X is a random variable, µ the populations mean and σ its standard
deviation.
Furthermore, Web-TCGA provides utilities to analyse and visualize the
methylation status. For more details the reader is referred to Deng et al [32],
as this data type is not used within the scope of this thesis.
3.6 Learning from Data
There exists a wide variety of terminology when is comes to the process
generating knowledge from data. Most prominently the terms information
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retrieval, data mining, machine and statistical learning should be mentioned.
While information retrieval and data mining have their focus on the side of
data generation and aggregation, machine and statistical learning are mainly
used when it comes to building models, their interpretation and conclusions.
While the main task of machine learning is to make predictions, statistical
learning aims to infer conclusions from such predictions and the models used
to generate them. Of course, these are fine lines and somewhat arbitrary,
which will be seen when different models are discussed, but they help to frame
the context of this work: The learning of information which are interpretable
by a user of a certain domain.
3.6.1 Supervised Learning
Machine or statistical learning can be subdivided into two major disciplines,
supervised and unsupervised learning. While the supervised task is to pre-
dict a measured label (outcome), based on a number of variables (predictors
or features), unsupervised learning aims to organize data into groups without
any pre-knowledge about the true label. Another distinction has to be made
for supervised problems, as they can be subdivided into regression and classi-
fication problems. For regression problems, the label to predict is continuous
(e.g. body hight or expectancy of life), while for classification problems the
label takes categorical states, such as home country or disease state. This
thesis only focusses on supervised classification problems, as for all studied
cases a true class label is available. A training set, which consists of observa-
tions and a label for various samples, is used to build a model. This model
is used afterwards to make predictions of new, unseen, samples, where the
true class is unknown.
3.6.2 Learning Functions
Any model performs a projection from the input variables X to the label Y .
This projection is performed by function and it is the trainings goal to identify
such a function, which minimizes the training error E. We assume X ∈ Rp
to be a real valued input vector of measurements for a single sample of p
features and Y ∈ G be the corresponding label, with the joint distribution
Pr(X, Y ). If there is no error within the measurements of vector X and Y
depends on X, then there exists a function f(·), such that f(X) = Y . That
at hand, the goal of any supervised classification model is the approximation
of a function fˆ(·), for which fˆ(X) = f(X) = Y . To evaluate the quality of
such an approximation, a loss function, L(·), is required, indicating how far
fˆ(·) is away from the true mapping function f(·). A simple loss function can
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be represented by a K ×K matrix L, where K = card(G) is the cardinality
of G and L(f(X), fˆ(X)) = 1f(X)6=fˆ(X). Therefore, the loss function takes a
value of 0, if a prediction is made correctly, 1 elsewise. For n samples, any
algorithm minimizes
E = L(f(X), fˆ(X)) = arg min
X
1
n
n∑
n=1
L(f(xi), yi), (3.2)
where, E is the mean error made by the model with respect to the training
data [47]. It is to say that the approximated function, fˆ(·), can be over
complex (e.g. when generated through a neural network) or fairly intuitive
(as for linear models). As some methods outperform others, they still might
by impractical due to their complex output and intractability.
3.6.3 Bias–Variance Trade-off
The bias-variance tradoff is a dilemma that occurs for every supervised learn-
ing problem. It describes the problem of the simultaneous minimization of
two error terms, the bias and the variance:
• The bias describes the problem of an algorithm, not being capable of
modelling the true relation between training data X and label Y . This
error is based on false assumptions made by the algorithm and known
as underfitting.
• The error of variance occurs if an algorithm reacts over-sensitive to
the training data. This results in an overfitting of the model, as the
algorithm interprets noise within the data as signal.
This dilemma takes a central role for classification tasks, as it holds true for
all supervised regression and classification models [74]. Ideally the model is
capable of detecting all relations between the input data and the correspond-
ing label, simultaneously keeping its property of generalization to unseen test
data. For example, a linear model may not fit the data in perfect detail, miss-
ing some observations, but provides a constant performance when evaluated
on test sets. Therefore it has low variance, but a high bias. This behaviour
corresponds to the bottom-left bullseye in figure 3.6. On the other hand, if
a spline is added to the regression model, it may perform very well on the
training data, but suffers from high variance in the test scenario. Applied
onto multiple test sets it tends to perform poorly or highly accurate for one
or the other set, then on the training set. Vice versa, this model has high
variance and low bias, as depicted in the top-right corner of figure 3.6. Given
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Figure 3.6: Simplified illustration of the bias-variance trade-off. Figure
slightly adapted from Scott Fortmann-Roe (http://scott.fortmann-roe.
com/docs/BiasVariance.html).
a set of training samples X1, . . . , Xn and corresponding labels Y1, . . . , Yn, we
aim to approximate the true relation f(·). Unlike the assumption made in
3.6.2, data X has noise to it and an error term, , is required. Therefore
an approximation of Yi = f(Xi) +  has to be performed. Also, as the ir-
reducible error, , is unknown, the models fit has to be measured for the
training and test set independently, seizing the models true performance and
error tolerance [47].
3.6.4 Model Interpretability
As machine learning effects a broad spectrum of critical areas, such as medicine,
criminal justice or the financial markets, there is strong a will to understand
and interpret these models. As the approximated function of any model is
just an imperfect assumption about a real-life process, there exists a certain
interest in understanding how an approximated function came to its deci-
sions.
A well organised review of motifs and required properties is given by Lipton
[81]. In his study on model interpretability he gives four motivators why it
is important to understand a models output.
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Trust: Simplified, a model can be taken as trustworthy if its shown to
perform well on the task it is trained for. But trust might also be more
subjectively. Therefore, a user might feel more comfortable with a model he
can totally understand. This might not be the case for speech recognition
on a dial service, but it’s becoming an issue, if the user invest money to a
certain stock, suggested by a model.
Causality: The main focus of modelling is to make predictions. But in
some scenarios, as in this thesis, models might be used to infer properties of
the underlying problem. For example, a simple regression model could reveal
the association between tobacco abuse and lung cancer. As for correlation,
not any association might imply causality, but they might point their user
into the right direction.
Transferability: Mostly, models are trained and evaluated on a data set
which is split into two chunks. The first chunk is used for training and
the second is used for evaluation (as discussed in 3.6.3). But how will this
model perform when brought into a productive environment. In real-life, a
model could be trained on gene expression data to classify patients regarding
their cancer status. Likely this model will become invalid and produce false
predictions if the underlying technology changes, such as the expression chip.
If a model is interpretable, transferring it becomes an easier task.
Informativeness: Sometimes the model itself doesn’t perform any auto-
mated task, it just suggests some likely options to user, as done in decision
support systems. As the model reduces an formal error, the user might be
interested in the real-world purpose of the suggested action.
Based in these motifs, properties regarding the model and its approximated
function can be defined, helping to evaluated a learner with respect to its
interpretability.
Transparency: A model is considered transparent, if its simulatable. Here
simulatability can be understood in the way, that the user is able to reproduce
the decision made, just with the input data and model parameters at hand.
To reproduce a fitted regression spline is intractable to a human without
any access to a computing machine, but also is the reproduction of a deep
classification tree (classification trees are discussed in 3.6.5) with thousands
of leaves.
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Decomposability: It should be guaranteed that each part of the model
- the input, the parameters, the calculation etc. - are assessable by the
user. This might be the case for decision trees, if the input variables are
defined clearly with respect to the user. But considering feature aggregation
procedures, like a principal component analysis (PCA), which accumulates
features to achieve a better prediction, predictors can become black boxes to
the user.
Algorithmic transparency: Undeniable users are able to understand the
procedures of recursive splitting and partitioning, made by trees. Whereas
it takes more to understand and reproduce the complex training process of a
neural network. Therefore, a model is simpler to understand of its underlying
algorithms are intuitive.
Post-Hoc interpretability: Even if the model trained well and only pro-
vides a non complex mapping function which is understandable to the user,
it is of interest to provide factors which simplify the decision being made.
Therefore, predictor variables could be extended with further information,
providing context for the user. Also it is an important factor, that the model
can be visualized well. When struggling with complex scenarios, a well visu-
alized model might allow to focus on the problem and not the model itself.
Lastly, examples should be given. Examples should be chosen in a way that
they are intuitive, so that the user can focus on the understanding of the
model, before investigating the decisions made.
These concepts are both, important and slippery at the same time. Is seems
clear that a single model cannot achieve all of the above goals. Therefore it is
always a trade-off between interpretability and accuracy. Complex problems
might be solved by simple and intuitive models, but with the cost of feature
engineering, violating one of the above criteria.
3.6.5 Established Models
To asses the value of the EDL, it is necessary to compare its performance to
other models. Here, four well known models are introduced, namely Support
Vector Machine (SVM) [25], random forest [12], multinomial regression [9]
and classification trees [13]. The models have been chosen with respect to
the analyzed data types, their complexity and interpretability. As a first
criterion, all models have to be capable of handling continuous, categorical
and binary predictor variables at the same time. This is required as a broad
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variety of data types is tested. Second, the SVM and random forest models
have been chosen, as they are known to perform well on complex data sets,
but remain difficult to interpret. Vice versa, the regression and tree models
are intuitive to interpret, but should not perform as good as the other models.
Further, all models react different to irreducible errors, introduced in 3.6.3,
and therefore show different behaviours regarding the bias-variance trade-off.
Multinomial Regression
First, the multinomial logistic regression, short multinomial regression, is
introduced. It generalizes the logistic regression model to handle multiclass
problems, therefore more than two discrete outcomes are possible. It assumes
that the label can be modeled as a weighted linear combination of the pre-
dictor variables, but is not perfectly predictable from a single variable. As
with other regression models, statistical independence and collinearity of the
predictor variables can be neglected [47]. Basically the model can be written
as
score(Xi, y) = βy ∗Xi, (3.3)
where Xi is the vector of observations of a single sample and y its correspond-
ing class. βy is the vector of weights to be multiplied with Xi, to model the
combinations. As the multinomial regression decomposes multi label clas-
sification into k − 1 binary classification problems, where k = card(y), the
above problem has to be solved k − 1 times. Therefore, one class has to be
chosen as reference beforehand and the final classification decision is made
by maximum class probability for each regression model. For each regres-
sion problem the identification of the coefficients from equation 3.3, is then
solved by Maximum a posteriori estimation (MAP). Here the implementation
by Venables and Ripley’s R package nnet8, described in [130], is used.
Classification Trees
Classification trees belong to oldest methods of classification and rely on the
concept of recursive partitioning. Here the rpart9 package for R has been
used, which implements the classification tree described by Breiman et al
[13]. In this implementation, the algorithm recursively splits the input data
X by testing each predictor variable and each of its values as threshold, to
8https://cran.r-project.org/package=nnet.
9https://cran.r-project.org/package=rpart.
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Figure 3.7: An outline of a decision tree. The splits within the tree (labeled
with T) are called nodes, and the outcomes (labeled with A,B and C) are
called leaves. The top node is called the root. Figure adapted from Breiman
et all [13].
minimize the gini index. With
GI(S) =
k∑
i=1
fi(1− fi), (3.4)
where k is the cardinality of y and fi that fraction of items labeled with
i. This gini index can be understood as a measure for set impurity. For
example, the gini index of a set a, a, a, a, b, b, b, c, c, c would be 0.66, as (0.4 ∗
(1− 0.4)) + (0.3 ∗ (1− 0.3)) + (0.3 ∗ (1− 0.3)) = 0.66. A more pure set would
be a, a, a, a, b, b, with (0.67 ∗ (1 − 0.67)) + (0.33 ∗ (1 − 0.33)) = 0.44. The
predictor and value combination yielding the smallest gini index is then used
to split the data. For the remaining data, this growing procedure is repeated
until all samples are represented by the tree. If it is not possible to perform
a pure split, the subset with the smallest gini index is chosen. This impure
subset is then searched again with the remaining predictors for a pure split.
This way the characteristic tree structure (see figure 3.7) is created. For this
algorithm the choice of the next split only relies on the current state. This is
referred to as greedy algorithm and introduces weaknesses, as the algorithm
performs a local optimization to find the current best split. This local search
does not aim to optimize any global criterion and tends to create overfitted
models [46]. To avoid overfitting, tree pruning is introduced. The pruning
procedure removes unimportant splits within in sequence, not exceeding a
purity threshold given by the user.
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Random Forest
A random forest is an ensemble method for classification and relies on multi-
ple bagged trees. To overcome the weaknesses associated with classification
trees, Breiman introduced the random forest model back in 2001 [12]. To
create a random forest, a fixed number of m bagged trees are grown and the
final classification decision is carried out by voting. Here, a bagged tree is
a tree grown by the mean of Bootstrap Aggregation (Bagging) (for details
on bagging the reader is referred to Breiman et al [11]). With bagging, n′
samples are drawn with replacement from the original n samples, forming
a new training set Di, the classification is then performed on the remaining
samples, which have not been chosen for training. The procedure is repeated
m times, while each tree has one vote for the classification of each sample.
By default n′ = n, yielding an expected ratio of (1− 1/e) ≈ 0.632 of training
to test cases. This procedure can be understood as meta-learning algorithm
as it is applicable to any classification or regression model. While random
forests are known to heavily increase the performance of trees, this model
becomes almost uninterpretable as often several hundreds or thousands of
trees are grown. In this work, the random forest implementation by Wright
et al is used [137].
Support Vector Machines
Other than the methods introduced before, SVMs can only be used for binary
classification and they require the input data to be linear separable. That is,
there exists a vector, called hyperplane,
0 = w ∗X + b, (3.5)
where w is a normal vector of X and b a simple scalar. For a better under-
standing figure 3.8 left shows linear separable data with a hyperplane and
its margins. All data points are labeled regarding the side of the hyperplane
they are located on. If their distance from a data point to the hyperplane is
high, there probability of belonging to the class is high and vice versa. Thus,
w and b have to chosen, so that equation 3.5 is fulfilled. If the input is not
linear separable, as shown in figure 3.8 right, exceptions can be made allow-
ing a fraction of samples to be miss-labeled while training. This is called soft
margin, while the first version is called hard margin. If the data is not linear
separable and soft margins are applied, then, for any hyperplane 3.5, there
exist xi ∈ X, such that
yi[w ∗ xi + b]  1, (3.6)
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margin
w·x+b=+1
w·x+b=−1
w·x+b=0
Figure 4.2 Margin and equations of the hyperplanes for a canonical maximum-
margin hyperplane. The marginal hyperplanes are represented by dashed lines on
the figure.
We define this representation of the hyperplane, i.e., the corresponding pair (w, b),
as the canonical hyperplane. The distance of any point x0 ∈ RN to a hyperplane
defined by (4.3) is given by
|w · x0 + b|
∥w∥ . (4.4)
Thus, for a canonical hyperplane, the margin ρ is given by
ρ = min
(x,y)∈S
|w · x+ b|
∥w∥ =
1
∥w∥ . (4.5)
Figure 4.2 illustrates the margin for a maximum-margin hyperplane with a canon-
ical representation (w, b). It also shows the marginal hyperplanes, which are the
hyperplanes parallel to the separating hyperplane and passing through the closest
points on the negative or positive sides. Since they are parallel to the separating
hyperplane, they admit the same normal vector w. Furthermore, by definition of a
canonical representation, for a point x on a marginal hyperplane, |w · x + b| = 1,
and thus the equations of the marginal hyperplanes are w · x+ b = ±1.
A hyperplane defined by (w, b) correctly classifies a training point xi, i ∈ [1,m]
when w · xi + b has the same sign as yi. For a canonical hyperplane, by definition,
we have |w · xi + b| ≥ 1 for all i ∈ [1,m]; thus, xi is correctly classified when
yi(w ·xi+b) ≥ 1. In view of (4.5), maximizing the margin of a canonical hyperplane
is equivalent to minimizing ∥w∥ or 12∥w∥2. Thus, in the separable case, the SVM
solution, which is a hyperplane maximizing the margin while correctly classifying all
training points, can be expressed as the solution to the following convex optimization
problem:
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ξi
ξj
w·x+b=+1
w·x+b=−1
w·x+b=0
Figure 4.3 A separating hyperplane with point xi classified incorrectly and point
xj correctly classified, but with margin less than 1.
notion of margin.
4.3 SVMs — non-separable case
In most practical settings, the training data is not linearly separable, i.e., for any
hyperplane w · x+ b = 0, there exists xi ∈ S such that
yi [w · xi + b] ̸≥ 1 . (4.21)
Thus, the constraints imposed in the linearly separable case discussed in section 4.2
cannot all hold simultaneously. However, a relaxed version of these constraints can
indeed hold, that is, for each i ∈ [1,m], there exist ξi ≥ 0 such that
yi [w · xi + b] ≥ 1− ξi . (4.22)
The variables ξi are known as slack variables and are commonly used in optimization
to define relaxed versions of some constraints. Here, a slack variable ξi measures
the distance by which vector xi violates the desired inequality, yi(w · xi + b) ≥ 1.
Figure 4.3 illustrates the situation. For a hyperplane w · x + b = 0, a vector xi
with ξi > 0 can be viewed as an outlier . Each xi must be positioned on the correct
side of the appropriate marginal hyperplane to not be considered an outlier. As a
consequence, a vector xi with 0 < yi(w · xi + b) < 1 is correctly classified by the
hyperplanew·x+b = 0 but is nonetheless considered to be an outlier, that is, ξi > 0.
If we omit the outliers, the training data is correctly separated by w · x + b = 0
with a margin ρ = 1/∥w∥ that we refer to as the soft margin, as opposed to the
hard margin in the separable case.
How should we select the hyperplane in the non-separable case? One idea consists
of selecting the hyperplane that minimizes the empirical error. But, that solution
Figure 3.8: Left: Linear separable data in a two dimensional space with one
possible maximum margin (hard margin). Right: Not linear separable data
where an exception is made (soft margin). Figure adapted by Mohri et al
[88].
which is not in agreement with 3.5. But with the introduction of the error
term (also known as slack term ) ξi, we can reformulate 3.5, such that
yi[w ∗ xi + b] ≥ 1− ξi. (3.7)
Here ξi is a measure of distance, describing the gap between xi and the
hyperplane. This is illustrated in figure 3.8, right. xi is classified incorrectly
and xj violates the hyperplane property. Hence, the error ξi is incorporated
proportionally to the distance for both samples.
As most data sets are, even with soft margins, not linear separable, the
SVM uses a transformation. Using a kernel function the data is transformed
into a higher dimensional space and tested for linear separability again. This
process is repeated until a hyperplane is found. The implementation used for
all classifications in this work relies on Changs libsvm [17] and realizes multi
class classification by solving k times one-versus-all classifications. Here the
distances to hyperplane are used as score and the model with the maximum
distance for a samples wins.
3.7 Classifier Design
The goal is to predict models which are accurate, yet interpretable according
the criteria introduced in 3.6.4. Hence, the result model should be read-
able and semantically intuitive to any user with knowledge of problems
domain. Also some measure of evidence should be provided, indicating the
importance or relevance of a decision being made. One model fulfilling the
criteria given, is the d ision list introduced by Rivest [106]. A decision list
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consists out of consecutive IF. . . THEN. . . rules and can be understood as
single path of a classification tree. Not only that this model is intuitive, it
also compares well to medical scoring systems such as the CHADS2 score
for stroke prediction [48] or ERB2 scoring systems, which are utilized for
breast and gastric cancer scoring models [117, 60]. While Rivest only pro-
vided the theoretical framework for decision lists, they where implemented
first by Quinlan and Quinlan [103, 104] afterwards, as a simplification of de-
cision trees. In the following, problems with established decision list methods
are discussed and a generative model to overcome weak spots is given. The
introduced algorithm solves the classification problem through global opti-
mization of a single decision list.
3.7.1 Interpretability versus Accuracy
The two most well known methods for the generation of a decision list are the
C4.5Rules algorithm by Quinlan [103] and the PART procedure, described
by Witten et al [45]. Both algorithms build decision lists by the means
of a classification tree model described in 3.6.5. Basically, both methods
collapse each path through the tree into a single rule, which is then pruned.
The resulting set of rules is assembled into a decision list using optimization
procedures. This has the benefit that the yet simple tree model becomes
even more intuitive. But, as these procedures rely on decision trees only,
resulting models are pretty unlike to exceed the classification accuracy of
their predecessor trees [74]. As there might be a small increase in accuracy,
due to rule pruning, the main drawback is, as discussed in 3.6.5, the greedy
procedure to grow the trees. Common approaches to overcome problems
introduced by greedy algorithms are boosting or bagging of the classification
models, as done with random forests (3.6.5). Utilizing such methods results
in complex and hard to understand models, as these techniques build their
decisions on the basis of several hundreds of models. Another way to improve
classification accuracy is the global optimization of the classification problem.
To optimize a decision tree, its initial structure has to be given upfront.
Therefore, the number of splits, the number of leaves, the leave labeling and
tree depth become additional model parameters, making it uncomfortable to
work with. Further, the search space becomes needlessly large (Bennett [5]
provides a summary on tree optimization). Most of those model parameters
can be avoided, if the problem is formulated as a decision list, as splits are
decided automatically by the lists structure and only the list length has be
given beforehand.
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3.7.2 The Evolutionary Decision List
A decision list consists of consecutive IF. . . THEN. . . rules. If one rule
does not apply, the next one is tested. If none of the rules apply, a default
rule is chosen. A single rule can be described by the context-free grammar
G = {N, T, F, S} (slightly adapted from Espejo et al [40]), with
F = { r u l e := IF a n t e c e d e n t THEN consequent |
ELSE l a b e l ;
a n t e c e d e n t := t e s t | a n t e c e d e n t & t e s t ;
t e s t := name o p e r a t o r v a l u e ;
o p e r a t o r := ==;
consequent := l a b e l }
T = {IF , THEN, &, name , va lue , ==, l a b e l }
N = { r u l e , a n t e c e d e n t , t e s t , opera tor , consequent }
S = r u l e
where F is the set of state transition functions, T the set of terminal symbols,
N the set of non-terminal symbols and S the set of start symbols. It is easy
to see that this grammar can only create languages, capable of testing pos-
itive predictor occurrences. Hence, boolean false expressions, numerical and
categorical variables are decomposed upfront (discussion provided in section
3.7.4). Using such a simple language reduces the search space drastically,
as the majority of decision problems are decided during feature engineering.
Vice versa, expanding the grammars operator set would create languages
that are capable of testing more complex expressions. As given by the gram-
mar, an antecedent can recursively be expanded to an arbitrary long series
of conditions, This number is called the rules cardinality. The grammar also
generates the default rule, which is necessary to terminate the decision list,
if no rule is applicable. To generate rules by this grammar, any arbitrary
algorithm for frequent item set mining can be utilized. Here the FP-Growth
algorithm by Borgelt [10] is used. This allows also to take the rule support
into account, requiring the rule to cover a certain amount of samples.
Due to the grammar which generates the rules, each rule can be inter-
preted as a nondeterministic pushdown automaton (PDA). This way, each
rule acts as a small program on its own, solving a sub-problem of the clas-
sification task. To from a global classifier, a population (figure 3.9 B) is
initialized from all available rules. The population initially consists out of ps
randomly assembled decision lists, where each decision list is of the prede-
fined length l. Based on this population a simple genetic algorithm iteratively
forms the global classifier. First, each lists performance is assessed using the
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hamming loss (see figure 3.9 C, ”Measure Performance”),
H(xi, yi) =
1
n
n∑
i=1
xor(xi, yi)
|Y | , (3.8)
where n is the number of samples, |Y | the labels cardinality, yi the samples
ground truth and xi it predicted label. That is, the fraction of false predic-
tions made by a decision list to the sum of all labels. The best decision lists
are determined by tournament selection, where two lists are chosen randomly
and the one with smaller hamming loss is tagged for breeding (see figure 3.9
C, ”Selection”). This approach is known to put less selective pressure onto
the population, yielding a slower convergence, but also providing a higher
chance to find the optimum [70]. Tagged decision lists are then considered
for breeding, figure 3.9 D, with equal chances for crossover and mutation.
The crossover operator randomly samples two lists from the tagged once,
defines a random splitting point and swaps their trailing rules, right behind
the splitting point. For a mutation, a decision list is chosen randomly and a
random rule is replaced random by a rule sampled from the set of all avail-
able ones. This process is repeated for a pre-defined number of generations,
G. During all generations, the best list found is kept aside and returned
after the genetic algorithm terminates. This list is the final decision list.
The idea of genetic programming was introduced by Koza [70] back in 1992.
During the past years this paradigm has helped to solve several optimization
problems, due to its flexibility. Compared to other numerical optimization
methods, such gradient decent, it is more likely to find a global optimum, but
can therefore be more time consuming. Other recently introduced decision
list construction techniques by Letham et al [78], Yang et al [139] and Wang
et al [132] rely on the Bayesian statistics and provide an alternative way
of construction. Initially introduced by Letham et al, a single decision list
assembled at random and then modified according to the posterior distribu-
tion. This reduces the memory footprint and calculation time, but introduces
additional burden on implementation. Also the model is only considered for
binary class prediction, which is unusable in the most cases. Executing such
a model with a meta algorithm, where the winner is determined by voting
or probability (as implemented by the SVM 3.6.5), would indeed carry out a
multi class prediction, but also obfuscate the interpretable decision list.
3.7.3 Precision & Confidence Intervals
To provide some further insights into the data and the fitted model, the
precision and confidence intervals (CI) for each rule are given. These coeffi-
cients are intended to provide a measure of correctness for each rule. Hence,
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Figure 3.9: The workflow of the EDL. In the first step, A, all available rules
are generated from a data matrix. Afterwards, in B, a set of decision lists, the
population, is initialized at random. C depicts the workflow of the genetic
algorithm, where the performance of each rule determined and the best rules
are selected for breeding. This process is repeated G times. For breeding, D,
rules are chosen at random from tournament and underground a crossover
or a mutation.
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Table 3.1: Decomposition of categorical predictor variables
V all V cat V dog V chicken
cat T F F
cat T F F
dog → F T F
chicken F F T
chicken F F T
chicken F F T
the number of true positives (TP) classified samples per rule, divided by the
number of samples classified by the rule in total,
P (R) =
tp
(tp+ fp)
. (3.9)
The series of decision rules can be treated as independent sequences of bino-
mial experiments, each with a cohort of size n and a success rate of tp. With
these parameters at hand, the confidence intervals for the observed outcome
can be calculated by the Clopper-Pearson interval. As it is sufficient to know,
that each experiment can be treated as binomial experiment, and therefore
the Clopper-Pearson interval applies, the reader is referred to Clopper and
Pearson [19] for more details on this particular method. In this work the
confidence intervals haven been calculated using the binom.test function
from the R core library.
3.7.4 Binary Data Representation
For the process of rule mining it is required that the data is in binary format.
That is, only binary states of a samples predictor can be taken into account.
As most of the test data sets (3.2) and aggregated cancer data sets (4.2) are
not available in this binary format they need to be converted. Categorical
predictor variables are decomposed by their cardinality k. Thus, each state
a categorical predictor can take is represented as its own binary predictor.
As shown in table 3.1, for one predictor with k = 3 states, this will result in
three separate predictors to represent all states.
For continuous predictors, the z-score (equation 3.1) is utilized first (if
not already applied), to normalize the data. This score indicates the number
of standard deviations above/below the mean. Therefore, the cuts can be
chosen naturally as a grain of detail. For n cuts chosen, this results in n+ 1
predictor variables.
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Table 3.2: A blank confusion matrix
F T
F TN FP
T FN TP
3.8 Performance Assessment
This work assesses and compares the performance of multiple models with
respect to their ability of predicting unseen samples. To put different models
in contrast, a unit of measure is required. Further, resampling techniques
are required to ensure that a model does not only perform well on its train-
ing data, but also when applied to a new set of samples. This section in-
troduces methods for performances assessment and resampling methods for
gaining statistical confidence from observed measurements. A confusion ma-
trix serves as basis for further calculations. This matrix provides an overview
of how the samples have been labeled, compared to their true class. A blank
confusion matrix is given in table 3.2. In this confusion matrix, TP equals
to the number of samples being of true and been labeled as such, true neg-
atives (TN) the number of samples being negative and labeled as such, false
positives (FP) the number negative samples being predicted as positive and
false negatives (FN) the number positive samples, which have been labeled
as negative. This concept can easily be extended to multi label classifica-
tion, where the rows of the matrix are labeled with true class labels and the
columns with the predicted ones.
3.8.1 Classifier Performance
Here, the performance of a classifier or model does not describe the time it
takes to execute on a data set. Rather it describes its capabilities on how
well it can be suited to a given set of samples. First, it should mentioned
that not all measures are suitable for all kinds of problems. For the most
cases analyzed in this work, a multi label classification problem is given.
Therefore, only measures to assess their performance are taken into account,
leaving out binary measures of performance. One of the most well known
and frequently used measures might be the classification accuracy
ACC =
(TP/TN)
(P +N)
=
(TP/TN)
(TP + TN + FN + FP )
. (3.10)
According to the confusion matrix from table 3.2, the accuracy is the fraction
of correctly classified samples to all samples. One drawback of this measure
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Table 3.3: An example for cat and dogs classification
dog cat
dog 25 75
cat 0 900
is its weak spot for vastly unbalanced data. For example, considering 1,000
samples, from which 100 are of class dog and the remaining samples of class
cat. A classifier which predicts the most samples as cat (as shown in table 3.3)
performs well, according to the measure of accuracy (ACC = 925/1000 =
0.925). Actually this classifier seems to work pretty well. Considering that
the detection of dogs is an important task, there is a high chance that a
model will seem to perform well (given its accuracy), but will actually miss
most of the dogs.
This error can be corrected by taking the expected accuracy into account.
The expected accuracy is the accuracy any random classifier is expected to
achieve on the given data. It is defined by
EA =
(TN + FP ) ∗ (TN + FN) + (FN + TP ) ∗ (FP + TP )
(TP + TN + FN + FP )2
. (3.11)
This expected accuracy at hand, the inter rater agreement can be calculated.
That is, the achieved accuracy under control of a random classifier and is
known as kappa statistic or Cohens kappa [20],
kappa = (ACC − EA)/(1− EA). (3.12)
Recap the cat and dog example, where most of the samples are classified as
cat. The kappa statistic would yield a result of (0.925 − 0.88)/(1 − 0.88) =
0.375, which is far more pessimistic than the plain accuracy.
As none of the considered problems is such far of balance as the example,
it is not expected that kappa and accuracy statistic differ that much. Still,
the kappa statistic is the measure considered at first sight. For convenience
the accuracy is given as a seconds measure.
3.8.2 K-Fold Cross Validation
The methods described in section 3.8.1 serve as a utility to measure how
well a model is adjusted to a data set, but it does not reflect how the model
will perform for predicting new cases. It might be possible that the model
achieves high accuracy on its training data, but performs poorly on unseen
cases. This phenomenon is known overfitting and takes place, if the models
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starts to follow the irreducible error (3.6.3) or noise within the set of training
samples. To ensure that the model has not been overfitted it is necessary to
validate its performance on an independent test cohort, which has not been
seen by the model during training. As the access to unseen samples might
be limited, it is common to split the cohort into two halfs, a training and a
test set. This way, a model can be trained and evaluated independently.
This technique comes with two major drawbacks. First, depending on
which samples are chosen for training, the difference between training and
test performance can be huge. Second, only fifty percent of the data are
used for training. This might effect the model, as statistical models tend to
perform better, the bigger the sample size. For a detailed discussion, the
reader is referred to James et al [62]. A simple, yet effective method to
overcome these flaws is called K-fold cross-validation. As depicted in figure,
3.10, K-fold cross-validation splits the available data into k chunks (here 5).
Afterwards, k − 1 chunks are used for training and the remaining chunk for
validation. This process is repeated k times, each time leaving out the kth
chunk for testing. Therefore, only a small fraction of samples is left out for
training. To choose the right k, the bias-variance trade-off from 3.6.3 has to
be taken into account. One might argue that choosing k = N might be a
good idea, where N is the number of samples. Despite from computational
burden, there are n models to be trained, the cross validation will show high
degree of variance. This is because all n training sets are very similar to each
other, while the single left out sample can be very distinct to the training
data. On the other hand, if k is chosen to low, a high bias will be observed,
as the model has not enough data to correct for noise. To summarize, k has
to be chosen with care. Empirically the choice of k = 5 or k = 10 have
proven to show test error rates that suffer neither from excessively high bias
nor from very high variance [62].
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FIGURE 5.5. A schematic display of 5-fold CV. A set of n observations is
randomly split into five non-overlapping groups. Each of these fifths acts as a
validation set (shown in beige), and the remainder as a training set (shown in
blue). The test error is estimated by averaging the five resulting MSE estimates.
chapters. The magic formula (5.2) does not hold in general, in which case
the model has to be refit n times.
5.1.3 k-Fold Cross-Validation
An alternative to LOOCV is k-fold CV. This approach involves randomly
k-fold CV
dividing the set of observations into k groups, or folds, of approximately
equal size. The first fold is treated as a validation set, and the method
is fit on the remaining k − 1 folds. The mean squared error, MSE1, is
then computed on the observations in the held-out fold. This procedure is
repeated k times; each time, a different group of observations is treated
as a validation set. This process results in k estimates of the test error,
MSE1,MSE2, . . . ,MSEk. The k-fold CV estimate is computed by averaging
these values,
CV(k) =
1
k
k∑
i=1
MSEi. (5.3)
Figure 5.5 illustrates the k-fold CV approach.
It is not hard to see that LOOCV is a special case of k-fold CV in which k
is set to equal n. In practice, one typically performs k-fold CV using k = 5
or k = 10. What is the advantage of using k = 5 or k = 10 rather than
k = n? The most obvious advantage is computational. LOOCV requires
fitting the statistical learning method n times. This has the potential to be
computationally expensive (except for linear models fit by least squares,
in which case formula (5.2) can be used). But cross-validation is a very
general approach that can be applied to almost any statistical learning
method. Some statistical learning methods have computationally intensive
fitting procedures, and so performing LOOCV may pose computational
problems, especially if n is extremely large. In contrast, performing 10-fold
Figure 3.10: A example of K fold cross-validation with k = 5. The data
1, 2, 3, . . . , n is split into five chunks. Afterwards five sets are created (each
shown in blue), each leaving out the kth chunk (shown in beige). This way,
11765 samples can be used for training, while 47 are used for validation.
Figure adapted from James et al [62].
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Chapter 4
Results
Fist, the results on the test data sets will be discussed. Afterwards, the de-
veloped EDL model is applied to a cohort of 1.000 breast cancer patients.
This is done as a proof of principle, to ensure that the model is capable
of both, labeling the samples according to their subtype and to re-identify
known subtype driver alterations. The achieved model accuracy is com-
pared to the accuracy achieved by the well established models. Following, a
newly assembled cohort of 500 patients, suffering from primary or metastatic
prostate cancer, is inspected using the EDL. Again, the accuracy is inspected
in the context of the well established models. For both investigations the co-
horts have been assembled using the FirebrowseR software and normalized
by the methods established through Web-TCGA, as described in 4.2. Finally,
the determined models are viewed under the aspects of their interpretability
3.6.4.
4.1 Test Data
The data sets introduced in 3.2 have been used by the machine learning
community for several years up to decades. They act as benchmark to com-
pare newly developed models to established ones. Since they are used by
a broad spectrum of people not only in the machine learning community,
common obstacles are known and improvements on classification accuracy
can be determined easily.
To have a fair comparison between the different models, all models, ex-
cept for the multinomial regression, have been tuned. For the SVM, the
slack parameter C and the γ radial-kernel parameter have been determined
using grid search with C ∈ {22, 20, . . . , 26} and γ ∈ {26, 24, . . . , 22}. For
the classification tree, the minimum split parameter has been tuned with
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msplit ∈ {1, 3, . . . , 19}, indicating the minimum number of samples in a node
to be considered for further splitting. Additionally, pruning has been uti-
lized to simplify and potentially improve the tree. The mtry parameter for
the random forest model, indicating the number of sampled predictors for
each split, has been chosen from log2(n), log10(n),
√
(n), n/2. As the multi-
nomial regression does not have a tuning parameter, it has been guaranteed
that the model converged. The list length parameter l for the EDL has been
tuned by hand, with respect to an upfront chosen prior.
With respect to the bias-variance trade-off introduced in 3.6.3, 10-fold
cross-validation has been utilized. During each run, each model has been
tuned on the k − 1 training samples and the final model performance has
been carried out by the kth test set. Kappa and accuracy are given as mean
with the corresponding SD, to detect potential outliers.
As these data sets are only used to compare EDLs performance to other
models, all decision lists are postponed to the appendix A.1.
4.1.1 The Tic Tac Toe data
The Tic Tac toe data consists of 9 categorical predictor variables, encoding
all possible states (958) of the tic tac toe game. The aim of the classification
model is to predict if player x has won.
As 3 identical symbols have to be present in either a row, a column
or in the diagonal of the game matrix, only rules of cardinality 3 need to
be generated. Longer rules not make any sense, as they wrap around the
gaming board, while shorter rules are not capable of detecting a victory.
Only rules with a rule support of at least 5% have been generated, yielding
152 classification rules in total. To create an EDL from those rules, the
genetic algorithm has been run for 50.000 generations and with a population
size of 152 decision lists. The length of each decision list was chosen to be 8,
as there are exactly 8 possible board configurations to win the game. For the
EDL model, the categorical variables have been decomposed as described in
3.7.4, resulting 27 binary predictors.
As shown in figure 4.1, it is clear to see that no other model, except to
the EDL, achieved a perfect classification for all ten runs. The results can be
viewed in more detail in table 4.1 and a final decision list, over all samples,
can be found in the appendix section A.1.1.
4.1.2 The Titanic data
The 3 categorical predictor variables form the titanic data set have been de-
composed 8 binary predictors. Out of these, 58 rules of cardinality 1, . . . , 4
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Figure 4.1: Boxplots indicate the classification performance (kappa statistic)
of all five models for the Tic Tac Toe data set. Scattering indicates the
10-fold cross-validation.
Table 4.1: Tic Tac Toe classification performance. Given measures are the
kappa statistic, accuracy and their SDs
Kappa Kappa SD Accuarcy Accuracy SD
EDL 1.000 0.000 1.000 0.000
Multinom Reg 0.957 0.032 0.980 0.016
Random Forest 0.869 0.060 0.943 0.028
Class Tree 0.812 0.095 0.916 0.040
SVM 0.963 0.024 0.983 0.011
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Figure 4.2: Boxplots indicate the classification performance (kappa statistic)
of all five models for the Titanic data set. Scattering indicates the 10-fold
cross-validation.
have been generated. The genetic algorithm has been run for 50.000 gener-
ations and the ideal decision list length was found to be 3. The results are
shown in figure 4.2 and table 4.2. After cross-validation, a final decision list
on all samples has been generated. This list is given in the appendix section
A.1.2 with the corresponding precision and confidence intervals.
4.1.3 The Mushrooms data
The mushrooms data set consist of 20 categorical predictors, which have been
decomposed to 111 binary predictors. Therewith 8116 rules of length 1, . . . , 3
and a minimum support 5% have been generated. The best performance
could be achieved with a list length of 8, where 20.000 generations were run
to build the model. The performance is given in figure 4.3 and table 4.3.
Again, a final decision list has been generated using all available data set
and is shown in A.1.3.
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Table 4.2: Titanic classification performance. Given measures are the kappa
statistic, accuracy and their SDs
Kappa Kappa SD Accuarcy Accuracy SD
EDL 0.429 0.044 0.791 0.022
Multinom Reg 0.439 0.070 0.778 0.026
Random Forest 0.411 0.054 0.781 0.029
Class Tree 0.421 0.046 0.788 0.025
SVM 0.432 0.073 0.776 0.027
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1.000
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a
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Figure 4.3: Boxplots indicate the classification performance (kappa statistic)
of all five models for the Mushrooms data set. Scattering indicates the 10-fold
cross-validation.
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Table 4.3: Mushrooms classification performance. Given measures are the
kappa statistic, accuracy and their SDs
Kappa Kappa SD Accuarcy Accuracy SD
EDL 1.000 0.000 1.000 0.000
Multinom Reg 1.000 0.000 1.000 0.000
Random Forest 1.000 0.000 1.000 0.000
Class Tree 0.988 0.006 0.994 0.003
SVM 1.000 0.000 1.000 0.000
Table 4.4: Cars Database classification performance. Given measures are the
kappa statistic, accuracy and their SDs
Kappa Kappa SD Accuarcy Accuracy SD
EDL 0.879 0.041 0.936 0.029
Multinom Reg 0.853 0.037 0.932 0.018
Random Forest 0.932 0.043 0.968 0.022
Class Tree 0.877 0.020 0.942 0.013
SVM 0.853 0.030 0.932 0.015
4.1.4 The Cars database
The cars data consists of 1728 samples, described by 6 categorical predictors.
These have been decomposed to 21 binary variables. 416 rules of length
1, . . . , 2 and a support of 1% have been generated. The genetic algorithm
ran for 20.000 generations, providing the best decision list with a length 25.
The decision list trained on all samples is depicted in appendix section A.1.4.
The classification performance to other models is depicted in figure 4.4 and
summarized in table 4.4.
4.1.5 Summary
As it can be seen, the EDL performed comparably well on all test data sets.
For the Tic Tac Toe problem, no other method performed as well as the EDL.
This is due the fact, that a lot of prior knowledge can be incorporated into
the model. It is clear that there are only 8 states to win the game (for player
x ), each consisting of exactly 3 predictor variables. This information can
be taken into account by the models parameters, reducing the search space
drastically and enabling EDL to find the global optimum. That important
observation confirms that the EDL it capable of finding the global optimum
if it exists. The reason the classification tree struggles at this problem, is be-
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Figure 4.4: Boxplots indicate the classification performance (kappa statistic)
of all five models for the Cars Database. Scattering indicates the 10-fold
cross-validation.
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cause of its greedy nature. The tree chooses the best split currently available.
Hence, at the root of the tree, negative examples are chosen first, because
more negative samples exist in the data set, which can be classified by a
single split. The random forest model is unlike to find the global optimum,
because of its voting system. Even if there exists several trees in the forest
indicating the perfect solution, this solution can not be carried out, as it gets
blurred by other trees during the process of voting. When inspecting the
generated decision list A.1.1, it can be seen that the EDL model found the
right combination of states, avoiding detours through combinations of non
optimal states.
For the Titanic data set, the generated decision list A.1.2 recovered the
policy by which the passengers have been rescued. Hence, children and female
passengers have been saved first, while passengers traveling third class had
a poor outcome of survival. As the discovered list gives an overview of
the odds of survival and death, slight modifications to the rule set might
reveal additional insights. Hence, the EDL could just be run with positive
or negative (survived/death) rules, yielding single label probabilities only.
Overall it should be mentioned that all of the methods performed well on
that problem. Except for the multinomial regression, showing strong outliers
regarding the kappa statistic.
The mushrooms data is another example, where the greedy strategy of
the classification tree results in a decrease of performance. Even if its just
a marginal effect, the tree is not capable to achieve a perfect classification.
All other methods, which optimize for a global maximum, can overcome this
issue. As a result, the EDL provide a decision list which can be used by
anybody to detect poisonous mushrooms A.1.3.
For the Cars Database the EDL performance is comparable to the other
models, but is clearly outperformed by the random forest. Further it shows a
high variance for the cross-validation, indication that noise has been learned.
As the overall performance seems acceptable, in special with a mean kappa
of 0.879, some flaws come along with the decision list model. The overall
decision list A.1.4 includes 25 rules with an additional default rule. This
might be to long to still call this model interpretable. Here it might be
worth to accept a less precise model, which in turn would yield a shorter and
more transparent set of rules.
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4.2 FirebrowseR + Web-TCGA = Data Foun-
dation
The breast 4.3 and prostate cancer 4.4 subtyping analyses are based on the
data sets obtained from the Firehose Pipeline. To obtain and normalize
these datasets, the FirebrowseR package and methods adapted from Web-
TCGA are adapted. The validity and applicability of the methods described
in 3.5 are elaborated in this section. To demonstrate the capabilities of Fire-
browseR, Web-TCGA and their combination, examples for each data type are
provided. As a proof of principle, analysis of well known mutations, expres-
sion profiles and CNVs are provided, highlighting the tools strengths when
working with genomic data obtained from TCGA or the Firehose Pipeline,
respectively.
4.2.1 Mutational Data
For mutational data, a global profile is created. This profile aggregates the
occurrences of somatic mutations of the genes TP53 , Teashirt Zinc Finger
Homeobox 3 (TSHZ3 ) and Von Hippel-Lindau Tumor Suppressor (VHL)
within the cancer entities of breast invasive carcinoma (992 samples) and
kidney renal clear cell carcinoma (437 samples). Within this cancer entities,
TP53 is known to be highly mutated in breast cancer, while VHL is known
for its hight mutation rate in the kidney clear cell carcinoma (for details see
Kandoth et al [65]). TSHZ3 is added as a negative control and should not
occur highly mutated in any of those entities. As shown in figure 4.5, TP53 is
highly mutated for breast cancer (32.5%) but is barely for the kidney entity
(1.8%). Vice versa, VHL is highly mutated in the entity of kidney renal
clear cell carcinoma (48.5%) but only on 1.4% of all breast cancer samples.
TSHZ3 , as negative control, shows mutation rates <1% in both entities.
4.2.2 Expression Data
For lung adenocarcinoma it is known that KRAS Proto-Oncogene, GTPase
(KRAS ), Epidermal Growth Factor Receptor (EGFR) and Transcription
Termination Factor 1 (TTF1 ) show higher levels of over expression, than
under expression [145, 95]. To re-identify those findings, the expression data
sets related to these genes and the cancer entity are download by Web-TCGA
over Firehose Pipeline. Then the z-score, equation 3.1, is used to calculate
the SD from the populations mean. Using these methods Web-TCGA in
combination with FirebrowseR was able to re-identify the described patterns
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Figure 4.5: The global mutation profile for TP53 , VHL and TSHZ3 within
the Breast and kidney cancer entities. While TP53 is highly mutated in
breast cancer, VHL shows almost no mutations. The reverse pattern is ob-
served for kidney renal clear cell carcinoma, where VHL is highly mutated.
In both entities, the negative control TSHZ3 , occurs <1% mutated. Figure
adapted from Deng et al [32].
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as depicted in 4.6. It is clear to see, that more samples suffer from an over,
than from an under expression.
4.2.3 Copy Number Variation Data
To handle CNV data, GISTIC2.0 is used by the Firehose Pipeline. There-
fore, each gene is characterized by a copy number level, either -2, -1, 0, 1,
2, encoding a homozygous deletion, a heterozygous loss, no change (diploid),
a gain and a high level amplification. To demonstrate the usability of this
data type for cancer classification, the CNV status for Fibroblast Growth
Factor Receptor 1 (FGFR1 ) and PIK3CA in lung squamous and lung ade-
nocarcinomas is compared. Findings depicted in figure 4.7 reflect the results
provided by Ciriello et al [18], where PIK3CA is highly amplified in more
than 50% of all lung squamous cell cancer entities, but only in 4% of all
lung adenocarcinomas. Furthermore, a high level amplification of FGFR1
is detected in more than 27% of all lung squamous cell cancer samples, but
only in a small subset of adenocarcinomas.
4.3 Breast Cancer Subtyping
As discussed in section 2.1, breast cancer is a heterogeneous disease, which
can be classified into several subtypes. While these subtypes are character-
ized by certain pattern, a crisp classification still seems impossible. Outgoing
from an initial clustering of expression profiles from breast cancer patients
[96], other more advanced methods and analyses have been introduced. These
incorporate additional data types [87, 92, 2] and were therefore able to pro-
vide a broader assessment of the disease, which let to a better understanding.
In this study, breast cancer and its known subtypes are utilized to eval-
uate the combination of EDL, the data provided over FirebrowseR and the
normalization procedures described in the context of Web-TCGA. Therefore,
using these techniques should yield identical results to state of the art mod-
els, recently published by Mo et al [87], Mer et al [85] and Curtis et al [27].
The combination of the introduced methods should be capable of detecting
the molecular subtypes, as well as the identification well known driver genes.
4.3.1 Assembling a Cohort
Breast cancer data has been obtained from Firehose Pipeline using the Fire-
browseR R client. Overall there where 1.097 samples available. There where
1.089 samples with copy number data, 977 samples with mutational data
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Figure 4.6: Expression profile for KRAS , EGFR and TTF1 on the lung ade-
nocarcinoma cohort obtained from FirebrowseR and analyzed Web-TCGA.
As expected, the well known oncogenes show an increased level of over ex-
pression. Figure adapted from Deng et al [32].
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Figure 4.7: CNV profile for FGFR1 and PIK3CA on lung adenocarcinoma
and lung squamous cell carcinoma cohorts. Pattern described by Ciriello
et al [18] could be re-identified using FirebrowseR and Web-TCGA. Figure
adapted from Deng et al [32].
and 1.093 with samples with expression data available. As neither TCGA
nor the Firehose Pipeline provide full PAM50 information, the annotations
have been adapted from Keenan et al [68]. After intersection of all TCGA
barcodes, 959 samples where identified, having mutational, copy number and
expression data available.
All applied analysis provide the mutational, expression and CNV status
for each gene. This results in several thousand predictor variables for each
analyses type, making the problem untraceable due to the combinatorial ex-
plosion (for more details on the combinatorial explosion, the reader is referred
to Venables et al [130]). Because of that, breaking down the number of pre-
dictors is a crucial task. For mutational data, only significant mutated genes
obtained from MutSig analyses [76], implemented in the Firehose Pipeline,
have been considered for analysis. For the CNV status, according to Kuhn
[74], predictor variables with zero or near zero variance1 and strongly cor-
related predictors2 have been dropped. For expression data, only PAM50
genes haven been taken into account. This let to 88 predictor variables for
the CNV status, 125 for the mutation status and 50 for the expression sta-
1Cutoff ratio for the most common value to the second most common value: 95/5.
2A cutoff of 90% pearson correlation has been applied.
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tus. As described in 3.7.4, all variables have been converted to binary form.
Each predictor for the expression data was converted to 5 binary predictors,
indicating high underexpression, low underexpression, no differential expres-
sion, low overexpression and high overexpression. These classes were defined
by calculating each genes z-score (equation 3.1), with the thresholds of two
and one standard deviations away from the populations mean, for positive
as for negative values. As GISTIC2.0 output is provided by the Firehose
Pipeline (3.5.4), each predictor can consist out of five copy number states.
These categorical predictors are decomposed to five binary predictors. After
decomposition 352 CNV and 250 expression predictors were determined. All
combined, together with the mutational data, this resulted in 677 binary
predictor variables.
4.3.2 Classifying Breast Cancer Subtypes
Decision rules where generated with a cardinality of 1, . . . , 3 and a support
of at least 5%, yielding 60,853 rules. The genetic algorithm was run for
100.000.000 generations and the ideal list length was found to be ten. As
usual, the population size was chosen the same number as rules exist, 60,853.
As proceeded with the test data, all other models were tuned as described in
4.1. The results are shown in figure 4.8 and table 4.5. It is clear to see that
the EDL does not perform as good as the SVM and the random forest(kappa:
0.704, 0.795 and 0.803), but still outperforms the multinomial regression and
classification tree model (kappa: 0.704, 0.501 and 0.659). Also the EDL
provides its results with a variance, comparable to the SVM and random
forest (0.042, 0.031 and 0.037). To ensure that the engineered features are
not hindering the classification and sufficient information is provided, the
results were compared to the finding of Mer et al [85]. Using a random forest
model, they achieved an accuracy of 0.87 for 800 breast cancer samples, which
compares well the random forest model trained here (accuracy: 0.852). It has
to be mentioned that Mer et al did only include PAM50 genes as predictor
variables. Therefore, an optimal classification can be provided, as the breast
cancer subtypes are defined by these 50 genes. Further, noise is introduced
into the cohort of this study, as additional data types are incorporated, from
which not every single predictor provides signal, but can potentially improve
the classification performance.
After ten fold cross-validation, a final decision list with the same model
parameters has been generated on all available samples. This list and a
corresponding classification graph is provided in figure 4.9.
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Figure 4.8: Boxplots indicate the classification performance (kappa statis-
tic) of all five models for Breast cancer data with PAM50 label. Scattering
indicates the 10-fold cross-validation.
Table 4.5: Breast cancer classification performance on PAM50 labels. Given
measures are the kappa statistic, accuracy and their SDs
Kappa Kappa SD Accuarcy Accuracy SD
EDL 0.704 0.042 0.776 0.055
Multinom Reg 0.501 0.049 0.612 0.041
Random Forest 0.803 0.037 0.852 0.027
Class Tree 0.659 0.058 0.743 0.044
SVM 0.795 0.031 0.845 0.023
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Her2 Subtype Surprisingly no ERB2 variation has been incorporated into
the decision list for the detection of the HER2 subtype, although this sub-
type is defined by an overexpression of this gene. Instead almost all samples
of this subtype can be characterized by a combination of the expression and
CNV status of six genes. For one thing, the Luminal A&B subtype specific
gene ESR1 is not known to be differentially expressed in the HER2 sub-
type, but is recorded with a low underexpression. A study by Denkert et al
[33] lately revealed correlations between the response to trastuzumab ther-
apy, indicating a good response for HER2 patients with an overexpression
of ESR1 , but no response was observed in ESR1 underexpressed samples.
This might an indicator for the poorer outcome for HER2 classified patients.
Another gene in the first rule is Forkhead Box C 1 (FOXC1 ), an inducer
of epithelial-to-mesenchymal transition (EMT) and already linked to the
HER2 subtype [124, 141]. Transmembrane Protein 45B (TMEM45B) and
Forkhead Box A1 (FOX1 ) from the seconds rule have initially been found
overexpressed by Parker et al [96] in one third of all HER2 samples. The
gain of Phenylethanolamine N-Methyltransferase (PNMT ) is likely to be an
artefact of an ERB2 gain, as its is located on the ERB2 amplicon.
Luminal B Subtype In two out of three Luminal B rules ESR1 occurs
overexpressed. This behaviour is one essential marker for the Luminal B
subtype in breast cancer. Despite from that, the important marker CCNB1
has been detected. CCNB1 regulates the cell proliferation and is commonly
active in Luminal B tumors, making them more aggressive compared to Lu-
minal A samples [98, 99].
Basal Subtype Two thirds of the Basal subtype is characterized by a
single rule, for the other third of samples the default rule is applied, indi-
cating that no sufficient information could be found. Within the single rule
which characterizes most of the basal samples MYB Proto-Oncogene Like 2
(MYBL2 ) was identified with an overexpression. Just as CCNB1 , MYBL2
is an important player for cell proliferation [98, 99]. Along with MYBL2 ,
Secreted Frizzled Related Protein 1 (SFRP1 ) it occurs within the basal rule.
SFRP1 is known to be key player in prostate cancer, effecting the Wnt sig-
naling pathway [63, 34]. For the last gene, NDC80, Kinetochore Complex
Component (NDC80 ) no association to cancer could be found.
Luminal A Subtype As well as for the Luminal B subtype ESR1 and
FOXA1 are found in the Luminal A subtype with the same pattern of alter-
ation. These samples are set apart by N-Acetyltransferase 1 (NAT1 ), PgR,
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Figure 4.9: The final decision list generated for breast cancer data set. On
the left hand side, the graph displays each rule applied (starting at 12 o’clock,
clockwise) with prediction made (inner circle) and true labels on the outer
circle. Numbers indicating the amount of TP samples (number < 5 are
omitted, due to reasons of space). Coloring is done regarding the subtype
and matched between both lists. The decision list on the right hand side
shows the classification rules, precision and the corresponding 95% confidence
intervals.
FOXC1 and Melanophilin (MLPH ). While NAT1 and MLPH are not asso-
ciated with either the Luminal A subtype nor any other, PgR is a key player
for breast cancer disease. It is observed overexpressed Luminal A&B tumors
and acts as a key marker for the choice of therapy [118, 56, 4]. Further,
the EMT inducer FOXC1 is found underexpressed in this subtype, which
be another indicator for the better outcome in contrast to Luminal B and
HER2.
Normal Subtype Within the single rule for the normal subtype only Cy-
clin E1 (CCNE1 ) is the only unseen gene in the decision list. This might be
due to fact that this subtype is known to show no molecular signatures. De-
spite from that, CCNE1 was identified to be distinct of this subtype. CCNE1
is associated with a poor outcome for breast and ovarian cancer [91, 69], with
a life expectancy of less than five years.
4.4 Prostate Cancer Subtyping
Prostate cancer is considered the male counterpart to breast cancer. Al-
though its primary type might not be as aggressive, prostate cancer forms
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different types of metastasis, decreasing the patients survival expectancy
drastically. To classify prostate cancer according to its molecular profiles
and to obtain predictions for survival rates from such profiles remains an
ongoing task. While for breast cancer the initial PAM50 subtypes have been
validated and proven as a reliable base, there is no such initial classification
scheme for prostate cancer, that could be validated. In this section, prob-
lems and contradictions with existing prostate cancer classification schemes
are discussed and an alternative model for the exploration of subtypes is pro-
posed. This model builds on the means of the elaborated methods used in
section 4.3 for breast cancer. The novel design of the cohort and the result-
ing decision list allow an accurate classification of primary and metastatic
prostate cancer samples. Additionally, the EDL sheds new light into the
underlying machinery driving prostate cancer progression and metastasis.
4.4.1 Designing a Cohort
As described in section 2.1, there exist a broad variety of prostate cancer clas-
sification schemes and proposed methods yielding potential subtypes. While
some methods rely on expression data only, others take advantage of addi-
tional genomic data types or meta information, such as pathways informa-
tion. Within their study You et al [140] compared their identified subtypes
to those propose by Tomlins et al [127] and the TCGA Network [93]. The
overlap of the predicted subtypes for all three studies is shown in figure 4.10.
As it is clear to see, there barely exists any overlap, obtruding the question
of reliability for the determined subtypes. While the TCGA network did not
provide any survival or relapse statistic, Tomlins et al could identify a small
but significant trend towards prostate cancer–specific mortality free survival
for one of their identified subtypes (called “triple negative“). At least, only
You et al could identify a decreased probability for metastatic free survival
for their PCS1 subtype, which is characterized by the expression of luminal
cell associated genes.
Despite from the problems discussed in section 2.2, all three studies rely
on different data types. While Tomlins et al and You et al used expression
data only, the TCGA Network utilized multiple data types. As all data,
except for the TCGA, is derived from different sources, batch effects could
heavily bias the outcome. Also, for most of the prostate cancer data available,
there is a lack of clinical and followup data. For example, the TCGA only
has follow up data for 2% of their prostate cancer patients available. Due to
those problems, it might be helpful not to identify potential subtypes first,
but to examine functional differences between primary and mCRPC. Also,
to avoid side effects, all samples should be processed in the same way and
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Figure 4.10: The suggested prostate cancer subtypes. In both figures the
subtypes by You et al are compared to the findings by the TCGA Network
(left) and Tomlins et al (right). PCS1, PCS2 and PCS2 denote the findings
made by You et al, other labels are adapted from the original publication.
Figure adapted from You et al [140].
meta predictors should be used as done in for the breast cancer data (4.3.1).
To overcome these obstacles, a cohort of 483 samples is analyzed by the
means of the methods developed in this study. The cohort consists of the
333 primary tumor samples used by the TCGA Network [93] and additional
150 mCRPC samples, used by Robinson et al [107]. Data for the 333 samples
is derived over the FirebrowseR software and the remaining 150 samples are
obtained from cBioPortals raw data download section. As discussed in the
Firehose and cBioPortal sections (3.4.2, 3.4.3), both portals rely on identical
datasets for their analyses, allowing an easy merge of their raw data sets.
Both cohorts provide CNV, mutational and fusion data. To merge them, a
set of genes commonly altered within prostate cancer is created. This set
serves as predictor variables in the EDL model. The list of 49 genes can be
found in the appendix A.2. For each gene, all alterations have been assessed.
Gene fusions have been encoded binary, denoting if a gene for a sample is
fused with any other gene. As proceeded with the breast cancer samples,
the CNV status has been decomposed to five states. Namely homozygous
deletion, heterozygous loss, no change (diploid), gain and amplification. As
mutational data can directly be used as binary predictor, no conversion is
required. This resulted in 343 binary predicted variables, 49 for mutations,
49 for gene fusions and 245 for the CNV status. Samples have been labeled
according to their cohort, primary or mCRPC.
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Table 4.6: Prostate Cancer Classification performance on primary and
mCRPC labels. Given measures are the kappa statistic, accuracy and their
SDs. All results are carried out by 10-fold cross-validation
Kappa Kappa SD Accuarcy Accuracy SD
EDL 0.877 0.029 0.950 0.013
Multinom Reg 0.751 0.111 0.896 0.048
Random Forest 0.922 0.069 0.967 0.028
Class Tree 0.775 0.099 0.911 0.039
SVM 0.917 0.068 0.965 0.028
4.4.2 Classifying Primary & mCRPC Samples
For 483 samples and the corresponding 343 features decision rules of car-
dinality 1, 2 and a minimum support of 1% have been generated, resulting
in 1,817 rules. The optimization using the genetic algorithm was run for
100,000,000 generations, with a population size of 1,817 decision lists. The
best performing decision list was found to be of length 14. Again, all other
models where tuned as described in 4.1 and the given results are determined
by 10-fold cross-validation. As shown in table 4.6, the EDL (kappa: 0.877)
clearly outperforms the multinomial regression (kappa: 0.751) and the classi-
fication tree (kappa: 0.775). Compared to the more advanced models, SVM
(kappa: 0.917) and random forest (kapp: 0.922), the EDL performs almost
as good. Also the EDL maintains the lowest standard deviation of all cross-
validation runs, yielding more reliable results. Additionally to the table, the
classification performs has been visualized using boxplots depicted in figure
4.11.
Eventually a final decision list, based on all samples, has been generated.
The decision list and the classification graph is depicted in figure 4.12. Con-
sidering that mCRPC is known to be more heterogeneous than the primary
type, the EDL could identify four rules which are specific to samples of the
non metastatic entity.
Primary Subtype
Interestingly the first rule of the decision list is specific to primary prostate
cancer. As the mCRPC samples are considered to be more heterogeneous,
this first rule, with a coverage of 9.5%, reveals outstanding characteristics
for the primary cohort. The rule consists of heterozygous losses for the
tumor suppressor gene TP53 and the AR pathway member NCOR1 . The
second rule for primary samples consists of gains for Phosphatidylinositol-4,5-
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Figure 4.11: Boxplots indicate the classification performance (kappa statis-
tic) of all five models for the Prostate cancer samples with primary and
metastatic labels. Scattering indicates the 10-fold cross-validation.
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Bisphosphate 3-Kinase Catalytic Subunit Beta (PIK3CB) and ETV1 only.
PIK3CB , a PI3K signaling pathway member, is likely to be upregulated due
Phosphatase And Tensin Homolog (PTEN ) loss (not covered by the list)
[93]. The ETV1 gain, an ETS transcription factor family (ETS) member,
is likely to cover the more rare ETS+ samples [127]. The last two rules
utilize Zinc Finger Homeobox 3 (ZFHX3 ) and ERG . As ZFHX3 is reported
to be frequently mutated within primary prostate tumor samples [6], this
heterogeneous loss might be the result of such mutations. The homozygous
deletion of ERG covers most of the identified samples. This is not surprising,
as an ERG fusion is observed in almost 50% of all primary tumor cases [128,
93], which could result in such a loss. Finally, for 158 primary tumor samples
no decision rule could be identified and therefore they are characterized by
the default rule.
mCRPC Subtype
While a couple of metastatic samples are classified by rules only covering a
small fraction of samples, the majority is identified by a single rule. This
rule, the second rule in the list, utilizes the amplification of AR to identify
52% of all metastatic samples. The remaining half of the metastatic samples
is largely identified by mutations to TP53 and AR and CNV changes to
Speckle Type BTB/POZ Protein (SPOP).
Final Decision List
Overall, exclusive alterations to NCOR1 , PIK3CB and ERG could be de-
tected and utilized on the primary cohort by EDL. Additional analyses re-
vealed that the heterozygous loss of AR regulator NCOR1 is exclusive to
12.2% of all primary patients on does not occur in metastatic samples (<1%).
A PIK3CB gain was found 9.5% of the samples. As PTEN -deleted tumors
likely depend on PIK3CB , due to the inhibition of PIK3CA, a co-occurring
alteration to PIK3CB and PTEN might effect the PI3K pathway output, as
suggested by Schwarz et al [111]. A homozygous deletion of ERG was found
in 10.4% of all primary samples, promoting a fusion with potential partners
such as TMPRSS2 .
In comparison, the only events which could be observed exclusive for
mCRPC samples were a gain of AR and mutations of AR. Although not at
the very first position, the gain of AR could be observed exclusively in 16.2%
of all cases. Also the mutation to AR takes place in 5.4% of all mCRPC
cases. Other alterations were not exclusive or nearly exclusive to one of the
two entities. Hence, the EDL made use of its hierarchical decision model and
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Figure 4.12: The final decision list generated for the prostate cancer data set.
On the left hand side, the graph displays each rule applied (starting at 12
o’clock, clockwise) with prediction made (inner circle) and true labels on the
outer circle. The numbers indicate the amount of TP samples (numbers < 1
omitted, due to reasons of space). Coloring is done regarding the subtype and
matched between both lists. The decision list on the right hand side shows the
classification rules, precision and the corresponding 95% confidence intervals.
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excluded the FPs first, before integrating an impure rule.
Chapter 5
Discussion
5.1 Data Aggregation & Normalization
With the spread of the internet, the process of data sharing became key in
the field of bio-medical research. Over the past years several publicly avail-
able platforms emerged. While, in the beginning, issue centric information
to a problem has been provided as a database [121], recently emerged ar-
chitectures act more as a dump for high-throughput data [66]. This led to
questions, which have not been addressed by the research community be-
fore. Hence, the researcher is not only confronted the evaluation of the data,
but more with a complete workflow requiring problem-specific fine tuning on
several levels. To overcome such obstacles in the field of cancer research,
the Firehose Pipeline has been implemented, enabling the access to almost
analyses ready data sets. But still, depending on the problem, several steps
are required to work with data sets derived from multiple high-throughput
technology resources.
To address theses problems, several approaches have been introduced,
spanning a broad space of application. Frameworks like TCGA2STAT [131],
RTCGAToolbox [109] and TCGA-Assembler [146] aim to enable easy ac-
cess to such data and pre-processing procedures provided by TCGA and
Firehose Pipeline, respectively. Comparing those software packages to Fire-
browseR, the first difference is the underlying software architecture, which
keeps FirebrowseR updated. Non of the other packages provides an auto-
mated update mechanism, often leaving the software product behind the
API schedule. When comparing the projects data sources, TCGA2STAT,
TCGA-Assembler and FirebrowseR all rest upon Firehose data only, while
RTCGAToolbox incorporates both, Firehose and TCGA data. This has the
advantage, that different levels of data can be accessed, which is not possible
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when relying on Firehose data only. Additionally RTCGAToolbox already
implements linear models and empirical Bayesian methods provided through
the limma [119] package, to determine differentially expressed genes. Based
on these models, a method for survival analyses is provided as well. Just as
RTCGAToolbox, TCGA-Assembler provides methods to merge different data
types into a single object, for multi platform analyses. Additionally, methods
to compare methylation data, derived from different platforms, are provided.
Just as FirebrowseR, TCGA2STAT provides no additional functionalities.
Despite from that, there are a number important differences between Fire-
browseR and all other packages. As FirebrowseR is the only package, which
relies on Firehose data only, while being fully compatible with the Firebrowse
API. While other packages require the user to download whole data dumps
organized by cohort and/or technology, FirebrowseR enables the targeted
download of pre-defined samples, genes and data types. This has the ad-
vantage, that no data overhead is obtained. Vice versa, a pre-defined set
of genes for a given technology must be provided, as the download of all
genomic information over an API would exceed its capacities. Also, as for
each data type a function on its own is provided by the Firehose Pipeline,
FirebrowseR realizes the download for each data type through a function
on its own. While this has the benefit of remaining compatible with the
API, it could complicate the first steps, if the user is new to TCGA and/or
Firebrowse.
The cBioPortal [16] provides an intuitive web-interface to analyse TCGA
and Firehose data on a coarse level. Additionally, the cohorts provided can be
downloaded for offline analyses, just as the results themself. When compar-
ing cBioPortal to the other software tools discussed, their different purpose
becomes clear. As the other tools are intended to make the data available to
the R programming environment, cBioPortal aims provides an exploratory
data-laboratory. Additionally, a software package for the R programming
environment is available [61], making cBioPortal functionalities accessible
from R. This package enables the access to the data portal for additional in-
vestigations within the programming environment. While Web-TCGA [32],
from which the normalization methods have been adapted, does not provide
such an abundance of features, their intended use remains identical. With
both utilities the user is able to investigate data on a coarse level, which
can be further downstreamed within the R programming environment. In
direct comparison, Web-TCGA does not provide survival and co-expression
analyses. However, these analyses can easily be added from within the R
environment by utilizing the FirebrowseR package.
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5.2 Evolutionary Decision List
The introduced EDL provides a powerful, yet easy to interpret alternative
to existing methods. While the model showed competitive results, when
compared to state of the art machine learning methods (section 4), there
still exists issues which need to be addressed in the future.
Technically the EDL is a machine learning model which consists out of two
different models. While the first one solves an association rule learning prob-
lem, the second model solves an optimization problem when constructing the
decision list. For the extraction of association rules from databases, a wide
variety of algorithms is available. The most prominent once are the Apriori
algorithm [1], the Eclat algorithm [142] and the FP-growth algorithm [10].
Although all algorithms perform an identical task, the algorithms choice still
remains important, when taking the database size into account. In this study,
only relatively small data sets have been investigated. While ranging from
several hundred, to several thousand samples and being described through
several hundred predictor variables, the FP-growth algorithm performed suf-
ficient. The particular choice becomes important, if the data sets become
larger. Therefore, the algorithm should be chosen with respect to the un-
derlying architecture and desired rule criteria [59]. That is, some algorithms
are designed for parallel or distributed computation, while other show better
performance when used to generate longer rules. Despite from the aspect of
scaling, different concepts of association rules could be taken into account.
For example, association rules covering multiple relations [36, 138] or mining
only context specific rules [112] should be investigated, as they might improve
the models performance with reference to accuracy and speed. The second
problem, the optimization of a decision list, is carried out by a simple genetic
algorithm. In this study crossover and mutation rates have been hold fixed,
also the population size has always been hold constant, with respect to the
number of generated rules. As genetic algorithms have been around for more
then 25 year now [70], there exists a large number of problem oriented ap-
proaches. Hence, mutation and crossover rates could be chosen with respect
to the current performance or performance progression during the evolu-
tionary procedure [102, 73]. Additionally, the proposed system operates on
decision lists of a fixed length only, adding an additional tuning parameter
to the model. Therefore, by allowing crossover operations without respect
to the list length, the system could automatically discover lists of optimal
size. While this would remove an additional tuning parameter, it introduces
a problem termed bloating [41, 102]. Bloating can result in extreme long
decision lists, being only marginal superior to short and intuitive list.
When comparing the introduced model to the Bayseian Rule List (BRL)
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by Letham and Yang1 [78, 139], the EDL is missing a measure of class prob-
ability. This is due to the simple genetic algorithm, which does not allow
probability estimates, but enables an easy implementation of the multi class
classification problem, which is not given for the BRL. Additional extensions,
based on these foundations, could be the monotone property. This property
has been introduced by Wang et al [132], where the class probabilities are
monotonically decreasing with descending list depth. This could be beneficial
for risk estimations of a single event in relation to additional observations.
Other properties, introduced by Goessling et al [49], are the routing of the
direction for the decision list. In the presented concept, one possible option
is the learning with a fixed default class, where the search space would be
“carved out“ for informative rules. The other option only learns rules for
one class, collapsing all remaining ones into a default class. This procedure
would be useful, when estimating likelihoods for a single group only.
The EDL embodies a model, fulfilling the criteria introduced in 3.6.4.
Hence, it provides i) transparancy, as the final model is simulatable, ii) de-
composability, as its input is intuitive to the user, iii) algorithmicly trans-
parent, as the algorithm is a simple echo of the darwinian evolution theory
and iv) post-hoc interpretable as the output is human readable and can be
visualized easily. Further, it can be modified easily, by changing the under-
lying concept of association rules, the set of class labels taken into account
or by changing the underlying optimization algorithm.
5.3 Breast Cancer Findings
For the analysis of breast cancer subtypes, the EDL represents an appropri-
ate tool. In terms of accuracy it outperforms the multinomial regression and
the classification tree, while being a bit less accurate than the SVM and the
random forest. Additionally, the EDL was able to identify almost all driving
alterations, by which the PAM50 subtypes are defined. Hence, for the detec-
tion of both luminal subtypes, the decision list utilized the overexpression of
ESR1 as a marker. ESR1 is used to define these two breast cancer subtypes,
as ER+ cancer cells depend on estrogen for their growth [96, 26]. Addition-
ally, CCNB1 has been chosen as predictor to distinguish the lumnial B from
luminal A samples. CCNB1 is a proliferation regulator and is considered to
be the driving force making the luminal B subtype more aggressive, than the
luminal A subtype [98, 99]. Also, PgR hast been chosen as a marker for the
detection of the luminal A subtype (PR+ subtype). Together with ESR1 this
gene is utilized to determine an appropriate hormone therapy form [108, 118].
1The model is identical, yet the implementation differs.
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While the EDL was capable to detect the genes by which the lumnial sub-
types are defined, it missed the detection of ERB2 . While ERB2 defines
the Her2 subtype, several Her2 samples are reported with an overexpression
of ESR1 and no overexpression of ERB2 itself, making the clear separation
difficult [57, 108]. As ESR1 was utilized within the first rule of the list, this
might explain why here no ERB2 marker was used, as ESR1 in combination
with Melanoma Inhibitory Activity (MIA) and FOXC1 might yield a better
classification performance.
While the EDL was able to achieve a competitive classification perfor-
mance, it only utilized expression data (with the exception of a PNMT gain)
within the final decision list. Although mutational and CNV data has been
incorporated as well. Hence, it was expected that mutations and CNVs of
the genes GATA3 , FOXA1 , PIK3CA and MAP3K1 would have been con-
sidered for classification as well, as they have been reported to be exclusively
altered in the luminal subtypes [92, 2]. For triple negative breast cancer
samples (basal like), a MYBL2 overexpression was identified as splitting
criterion. MYBL2 is proliferation marker which has already been observed
overexpressed in breast cancer [126]. Due to ambiguous patterns for the Her2
subtype, a combination of ESR1 , FOXC1 and MIA was chosen to identify
most of Her2 samples.
In sum, the EDL correctly identified the driver genes for luminal subtypes
and the true marker gene to distinguish the luminal A from the luminal B
subtype. In addition known marker genes for the basal subtype could be
re-identified correctly, while the significant marker for the Her2 subtype has
been missed. Further, a novel signature of genes (associated with a poor
disease outcome in general) for the normal subtype was identified, reliably
separating those samples from the others.
5.4 Prostate Cancer Findings
After it has been shown that the EDL is an appropriate classifier in general
and capable of classifying cancer subtypes, with the additional ability to
unveil the important, subtype specific, predictors, a final evaluation on the
aggregated data set of prostate cancer samples has been performed. During
the 10-fold cross validation runs the EDL achieved results which compared
well to the state of the art models, SVM and random forest. It clearly
outperformed both models which are considered interpretable, while holding
the properties introduced in 3.6.4. Further, there was no other model showing
such a low degree of SD during cross-validation, highlighting the stability for
classification.
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The finally aggregated decision list revealed known and novel finding be-
tween primary and metastatic prostate cancer samples.
It is known that primary prostate cancer suffers less frequent from mu-
tations and CNVs compared to mCRPC [107, 93, 54]. However, the EDL
identified a decision rule to distinguish primary from metastatic cases by
utilizing several genes affected through mutations and CNVs. In particular
it identified a subgroup of samples by two specific gains, which are only ob-
served in the primary cohort. The genes utilized by that first rule, TP53 and
NCOR1 , have previously been observed in both cohorts, but not attracted
attention as a unique characteristic [107, 93] for any subtype. While in com-
bination, their heterozygous loss is specific to 10% of all primary samples.
This is contrary to observations made in breast cancer, where NCOR1 has
been reported mutated and differentially expressed in lymph node metasta-
sis [144]. Another important finding is the identification of the homozygous
ERG deletion. While a gene fusion between TMPRSS2 and ERG is ob-
served in 50% of all primary prostate cancer samples [6, 129], the partial
deletion of ERG can be considered as a precursor for this event. Another
novel finding is that the AR was found to be gained in more than 50% of all
mCRPC samples, but not in the previously identified set of primary samples,
harbouring a NCOR1 /TP53 variant. It is the AR which is therapeutically
drugged, but to which mCRPC patients develop a resistance. As the AR is
normally observed gained in both states of the disease [123, 113], it has be
not been under consideration as a distinguishing marker. On the other hand,
the AR regulator NCOR1 was found to be exclusive for primary samples,
which might determine a preliminary stage for the gain of AR.
In comparison to other studies which proposed prostate cancer subtypes
[127, 93, 140], this study differs as it investigates potential subtypes by as-
suming primary and metastatic prostate cancer as given class labels, which
are then investigated by the EDL model. Compared to the other cluster-
ing approaches, this procedure seemes more target-aimed, as all the other
studies totally disagreed on the their identified subtypes (figure 4.10). Fur-
ther, it remains unclear if mCRPC samples had been included. While there
have been subtypes identified which differ in survival [140, 127, 84], such an
analysis could not be provided here, as the data is not available for the inves-
tigated cohorts. Additionally, there is no data available whether the patient
has already undergone a therapy, which could bias the outcome. Also, prior
studies mostly defined prostate cancer subtypes by the TMPRSS2 :ETS fu-
sion status. This allowed for correlations with survival probability, but led
to conflicts with respect to grade and the probability of forming metastasis
and [75, 54, 125].
When inspecting the decision list itself (figure 4.12), the biggest group
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consists out of 158 primary samples. For these samples no specific alteration
could be found. Here additional investigations should be performed, includ-
ing a broader range of potential genes and genomic data types. Further, due
to its heterogeneity [107, 54], several rules applying for only a small portion
of mCRPC samples, have been utilized. These rules could potentially be
collapsed by identifying common alterations for the mCRPC samples, or by
expanding the rule cardinality. It is to say that all findings are based in
computational analyses and require a wet laboratory evaluation, based on
an independent cohort. Nevertheless, the findings revealed by the EDL shed
novel light into the yet sparsely understood process of mCRPC development.
Hence, the combination of TP53 and NCOR1 as novel distinguishing marker
for primary cases, as well as the AR gain for metastatic cases deserve and
require additional investigations, but provide a promising starting point for
follow-up studies.
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Chapter 6
Conclusion
In conclusion this study showed the usability of multi omics data types for
cancer subtype classification. To achieve this goal, it has been shown that
data obtained using the newly developed FirebrowseR software and normal-
ization methods adapted from Web-TCGA provide an ideal foundation for
such an analyses.
A newly developed classifier, the evolutionary decision list, has been
proven as reliable model for cancer subtype classification, achieving com-
petitive results to state of the art machine learning models. Through its
structure, the model automatically provides a build in mechanism for fea-
ture selection and model interpretation which is na¨ıvely amenable to any
user with knowledge of the problem domain. Benchmarks run on well known
example data sets underlined the models performance in competition with
established highly accurate and easy-to-interpret models.
The combination of FirebrowseR, data normalization methods and the
EDL was able to re-identify the known breast cancer subtypes and high-
lighted the important marker alterations of ERB2 , ESR1 , PgR and CCNB1 ,
by which these subtypes are defined. For the novel classification of primary
and metastatic prostate cancer samples, the method utilized well known
genes, which have not been considered as unique characteristic to one of
the two cohorts. Hence, a combined gain of TP53 and NCOR1 is specific to
primary prostate cancer, while a gain of the AR describes more than 50% of
all mCRPC samples.
77
78 CHAPTER 6. CONCLUSION
Bibliography
[1] Rakesh Agrawal, Ramakrishnan Srikant, et al. Fast algorithms for
mining association rules. In Proc. 20th int. conf. very large data bases,
VLDB, volume 1215, pages 487–499, 1994.
[2] Shantanu Banerji, Kristian Cibulskis, Claudia Rangel-Escareno,
Kristin K Brown, Scott L Carter, Abbie M Frederick, Michael S
Lawrence, Andrey Y Sivachenko, Carrie Sougnez, Lihua Zou, et al.
Sequence analysis of mutations and translocations across breast cancer
subtypes. Nature, 486(7403):405–409, 2012.
[3] Christopher E Barbieri and Scott A Tomlins. The prostate cancer
genome: perspectives and potential. In Urologic Oncology: Seminars
and Original Investigations, volume 32, pages 53–e15. Elsevier, 2014.
[4] Katrina R Bauer, Monica Brown, Rosemary D Cress, Carol A Parise,
and Vincent Caggiano. Descriptive analysis of estrogen receptor (er)-
negative, progesterone receptor (pr)-negative, and her2-negative inva-
sive breast cancer, the so-called triple-negative phenotype. Cancer,
109(9):1721–1728, 2007.
[5] Kristin P Bennett. Global tree optimization: A non-greedy decision
tree algorithm. Computing Science and Statistics, pages 156–156, 1994.
[6] Michael F Berger, Michael S Lawrence, Francesca Demichelis, Yotam
Drier, Kristian Cibulskis, Andrey Y Sivachenko, Andrea Sboner,
Raquel Esgueva, Dorothee Pflueger, Carrie Sougnez, et al. The genomic
complexity of primary human prostate cancer. Nature, 470(7333):214–
220, 2011.
[7] Tim Berners-Lee, Roy Fielding, and Henrik Frystyk. Hypertext trans-
fer protocol–http/1.0. Technical report, 1996.
79
80 BIBLIOGRAPHY
[8] Marko Bohanec and Vladislav Rajkovic. Knowledge acquisition and
explanation for multi-attribute decision making. In 8th Intl Workshop
on Expert Systems and their Applications, pages 59–78, 1988.
[9] Dankmar Bo¨hning. Multinomial logistic regression algorithm. Annals
of the Institute of Statistical Mathematics, 44(1):197–200, 1992.
[10] Christian Borgelt. An implementation of the fp-growth algorithm. In
Proceedings of the 1st international workshop on open source data min-
ing: frequent pattern mining implementations, pages 1–5. ACM, 2005.
[11] Leo Breiman. Bagging predictors. Machine learning, 24(2):123–140,
1996.
[12] Leo Breiman. Random forests. Machine learning, 45(1):5–32, 2001.
[13] Leo Breiman, Jerome Friedman, Charles J Stone, and Richard A Ol-
shen. Classification and regression trees. CRC press, 1984.
[14] Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T
Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L
Graham, and Charles M Perou. The triple negative paradox: primary
tumor chemosensitivity of breast cancer subtypes. Clinical cancer re-
search, 13(8):2329–2334, 2007.
[15] Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler,
David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester,
Chiu Kit Tse, Sharon Edmiston, et al. Race, breast cancer subtypes,
and survival in the carolina breast cancer study. Jama, 295(21):2492–
2502, 2006.
[16] Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Sel-
cuk Onur Sumer, Bu¨lent Arman Aksoy, Anders Jacobsen, Caitlin J
Byrne, Michael L Heuer, Erik Larsson, et al. The cbio cancer genomics
portal: an open platform for exploring multidimensional cancer ge-
nomics data, 2012.
[17] Chih-Chung Chang and Chih-Jen Lin. Libsvm: a library for support
vector machines. ACM Transactions on Intelligent Systems and Tech-
nology (TIST), 2(3):27, 2011.
[18] Giovanni Ciriello, Martin L Miller, Bu¨lent Arman Aksoy, Yasin Sen-
babaoglu, Nikolaus Schultz, and Chris Sander. Emerging land-
scape of oncogenic signatures across human cancers. Nature genetics,
45(10):1127–1133, 2013.
BIBLIOGRAPHY 81
[19] Charles J Clopper and Egon S Pearson. The use of confidence or fiducial
limits illustrated in the case of the binomial. Biometrika, 26(4):404–
413, 1934.
[20] Jacob Cohen. A coefficient of agreement for nominal scales. Educational
and psychological measurement, 20(1):37–46, 1960.
[21] Mary McNaughton Collins and Michael J Barry. Controversies in
prostate cancer screening: analogies to the early lung cancer screen-
ing debate. Jama, 276(24):1976–1979, 1996.
[22] Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, and
Jorge S Reis-Filho. Microarrays in the 2010s: the contribution of
microarray-based gene expression profiling to breast cancer classi-
fication, prognostication and prediction. Breast Cancer Research,
13(3):212, 2011.
[23] Colin S Cooper, Rosalind Eeles, David C Wedge, Peter Van Loo, Gunes
Gundem, Ludmil B Alexandrov, Barbara Kremeyer, Adam Butler,
Andrew G Lynch, Niedzica Camacho, et al. Analysis of the genetic
phylogeny of multifocal prostate cancer identifies multiple independent
clonal expansions in neoplastic and morphologically normal prostate
tissue. Nature genetics, 47(4):367–372, 2015.
[24] Matthew R Cooperberg, Jeanette M Broering, and Peter R Car-
roll. Risk assessment for prostate cancer metastasis and mortality
at the time of diagnosis. Journal of the National Cancer Institute,
101(12):878–887, 2009.
[25] Corinna Cortes and Vladimir Vapnik. Support-vector networks. Ma-
chine learning, 20(3):273–297, 1995.
[26] Chad J Creighton et al. The molecular profile of luminal b breast
cancer. Biologics, 6(2):289–297, 2012.
[27] Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili,
Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch,
Shamith Samarajiwa, Yinyin Yuan, et al. The genomic and transcrip-
tomic architecture of 2,000 breast tumours reveals novel subgroups.
Nature, 486(7403):346–352, 2012.
[28] Anthony V D’amico, Richard Whittington, S Bruce Malkowicz, Delray
Schultz, Kenneth Blank, Gregory A Broderick, John E Tomaszewski,
Andrew A Renshaw, Irving Kaplan, Clair J Beard, et al. Biochemical
82 BIBLIOGRAPHY
outcome after radical prostatectomy, external beam radiation therapy,
or interstitial radiation therapy for clinically localized prostate cancer.
Jama, 280(11):969–974, 1998.
[29] Petr Danecek, Adam Auton, Goncalo Abecasis, Cornelis A Albers,
Eric Banks, Mark A DePristo, Robert E Handsaker, Gerton Lunter,
Gabor T Marth, Stephen T Sherry, et al. The variant call format and
vcftools. Bioinformatics, 27(15):2156–2158, 2011.
[30] Johann Sebastian De Bono, Stephane Oudard, Mustafa Ozguroglu,
Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenae¨lle
Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen, et al. Prednisone
plus cabazitaxel or mitoxantrone for metastatic castration-resistant
prostate cancer progressing after docetaxel treatment: a randomised
open-label trial. The Lancet, 376(9747):1147–1154, 2010.
[31] Mario Deng, Johannes Bra¨gelmann, Ivan Kryukov, Nuno Saraiva-
Agostinho, and Sven Perner. Firebrowser: an r client to the broad
institute’s firehose pipeline. Database, 2017:baw160, 2017.
[32] Mario Deng, Johannes Bra¨gelmann, Joachim L Schultze, and Sven
Perner. Web-tcga: an online platform for integrated analysis of molec-
ular cancer data sets. BMC bioinformatics, 17(1):72, 2016.
[33] Carsten Denkert, Jens Huober, Sibylle Loibl, Judith Prinzler, Ralf Kro-
nenwett, Silvia Darb-Esfahani, Jan C Brase, Christine Solbach, Keyur
Mehta, Peter A Fasching, et al. Her2 and esr1 mrna expression levels
and response to neoadjuvant trastuzumab plus chemotherapy in pa-
tients with primary breast cancer. Breast Cancer Research, 15(1):R11,
2013.
[34] Theresa A DiMeo, Kristen Anderson, Pushkar Phadke, Chang Feng,
Charles M Perou, Steven Naber, and Charlotte Kuperwasser. A novel
lung metastasis signature links wnt signaling with cancer cell self-
renewal and epithelial-mesenchymal transition in basal-like breast can-
cer. Cancer research, 69(13):5364–5373, 2009.
[35] Brenton R Dobin, Sheng Li, Christopher E Mason, Sara Olson, Dmitri
Pervouchine, Cricket A Sloan, Xintao Wei, Lijun Zhan, and Rafael A
Irizarry. A benchmark for rna-seq quantification pipelines.
[36] Sasˇo Dzˇeroski. Multi-relational data mining: an introduction. ACM
SIGKDD Explorations Newsletter, 5(1):1–16, 2003.
BIBLIOGRAPHY 83
[37] Dirk Eddelbuettel. Seamless R and C++ integration with Rcpp.
Springer, 2013.
[38] Dirk Eddelbuettel and Romain Francois. Rcpp: Seamless r and c++
integration. Journal of Statistical Software, 40(1):1–18, 2011.
[39] Paul AW Edwards. Fusion genes and chromosome translocations in the
common epithelial cancers. The Journal of pathology, 220(2):244–254,
2010.
[40] Pedro G Espejo, Cristo´bal Romero, Sebastia´n Ventura, and Ce´sar
Herva´s. Induction of classification rules with grammar-based genetic
programming. In Conference on Machine Intelligence, pages 596–601,
2005.
[41] Pedro G Espejo, Sebastia´n Ventura, and Francisco Herrera. A sur-
vey on the application of genetic programming to classification. IEEE
Transactions on Systems, Man and Cybernetics, Part C: Applications
and Reviews, 40(2):121–144, 2010.
[42] Roy Fielding, Jim Gettys, Jeffrey Mogul, Henrik Frystyk, Larry Mas-
inter, Paul Leach, and Tim Berners-Lee. Hypertext transfer protocol–
http/1.1. Technical report, 1999.
[43] Karim Fizazi, Michael Carducci, Matthew Smith, Ronaldo Damia˜o,
Janet Brown, Lawrence Karsh, Piotr Milecki, Neal Shore, Michael
Rader, Huei Wang, et al. Denosumab versus zoledronic acid for treat-
ment of bone metastases in men with castration-resistant prostate can-
cer: a randomised, double-blind study. The Lancet, 377(9768):813–822,
2011.
[44] Karim Fizazi, Howard I Scher, Arturo Molina, Christopher J Logo-
thetis, Kim N Chi, Robert J Jones, John N Staffurth, Scott North,
Nicholas J Vogelzang, Fred Saad, et al. Abiraterone acetate for treat-
ment of metastatic castration-resistant prostate cancer: final overall
survival analysis of the cou-aa-301 randomised, double-blind, placebo-
controlled phase 3 study. The lancet oncology, 13(10):983–992, 2012.
[45] Eibe Frank and Ian H Witten. Generating accurate rule sets without
global optimization. 1998.
[46] Mark A Friedl and Carla E Brodley. Decision tree classification of
land cover from remotely sensed data. Remote sensing of environment,
61(3):399–409, 1997.
84 BIBLIOGRAPHY
[47] Jerome Friedman, Trevor Hastie, and Robert Tibshirani. The elements
of statistical learning, volume 1. Springer series in statistics Springer,
Berlin, 2001.
[48] Brian F Gage, Amy D Waterman, William Shannon, Michael Boechler,
Michael W Rich, and Martha J Radford. Validation of clinical classifi-
cation schemes for predicting stroke: results from the national registry
of atrial fibrillation. Jama, 285(22):2864–2870, 2001.
[49] Marc Goessling and Shan Kang. Directional decision lists. In Big Data
(Big Data), 2015 IEEE International Conference on, pages 2762–2766.
IEEE, 2015.
[50] A 2011 Goldhirsch, WC Wood, AS Coates, RD Gelber, B Thu¨rlimann,
H-J Senn, et al. Strategies for subtypes—dealing with the diversity of
breast cancer: highlights of the st gallen international expert consensus
on the primary therapy of early breast cancer 2011. Annals of oncology,
page mdr304, 2011.
[51] Aron Goldhirsch, WC Wood, RD Gelber, AS Coates, B Thu¨rlimann,
H-J Senn, et al. Progress and promise: highlights of the international
expert consensus on the primary therapy of early breast cancer 2007.
Annals of oncology, 18(7):1133–1144, 2007.
[52] Martin Gollery. Bioinformatics: Sequence and genome analysis, david
w. mount. cold spring harbor, ny: Cold spring harbor laboratory press,
2004, 692 pp.. isbn 0-87969-712-1. Clinical Chemistry, 51(11):2219–
2219, 2005.
[53] British Government. Report on the Loss of the S.S. Titanic. St Martin’s
Press, 1998.
[54] Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Sara-
vana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing,
Robert J Lonigro, J Chad Brenner, et al. The mutational landscape of
lethal castration-resistant prostate cancer. Nature, 487(7406):239–243,
2012.
[55] Peter Grimm, Ignace Billiet, David Bostwick, Adam P Dicker, Steven
Frank, Jos Immerzeel, Mira Keyes, Patrick Kupelian, W Robert Lee,
Stefan Machtens, et al. Comparative analysis of prostate-specific anti-
gen free survival outcomes for patients with low, intermediate and high
risk prostate cancer treatment by radical therapy. results from the
BIBLIOGRAPHY 85
prostate cancer results study group. BJU international, 109(s1):22–
29, 2012.
[56] M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig
Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn
Francis, Neil S Goldstein, Malcolm Hayes, et al. American society of
clinical oncology/college of american pathologists guideline recommen-
dations for immunohistochemical testing of estrogen and progesterone
receptors in breast cancer (unabridged version). Archives of pathology
& laboratory medicine, 134(7):e48–e72, 2010.
[57] Reina Haque, Syed A Ahmed, Galina Inzhakova, Jiaxiao Shi, Chan-
tal Avila, Jonathan Polikoff, Leslie Bernstein, Shelley M Enger, and
Michael F Press. Impact of breast cancer subtypes and treatment on
survival: an analysis spanning two decades. Cancer Epidemiology and
Prevention Biomarkers, 21(10):1848–1855, 2012.
[58] Julia H Hayes and Michael J Barry. Screening for prostate cancer with
the prostate-specific antigen test: a review of current evidence. Jama,
311(11):1143–1149, 2014.
[59] Jochen Hipp, Ulrich Gu¨ntzer, and Gholamreza Nakhaeizadeh. Algo-
rithms for association rule mining—a general survey and comparison.
ACM sigkdd explorations newsletter, 2(1):58–64, 2000.
[60] M Hofmann, O Stoss, D Shi, R Bu¨ttner, M Van De Vijver, W Kim,
A Ochiai, J Ru¨schoff, and T Henkel. Assessment of a her2 scoring sys-
tem for gastric cancer: results from a validation study. Histopathology,
52(7):797–805, 2008.
[61] A Jacobsen. cgdsr: R-based api for accessing the mskcc cancer ge-
nomics data server (cgds). R package version, 1:30, 2013.
[62] Gareth James, Daniela Witten, Trevor Hastie, and Robert Tibshirani.
An introduction to statistical learning, volume 6. Springer, 2013.
[63] Margaret S Joesting, Steve Perrin, Brian Elenbaas, Stephen E Fawell,
Jeffrey S Rubin, Omar E Franco, Simon W Hayward, Gerald R Cunha,
and Paul C Marker. Identification of sfrp1 as a candidate mediator
of stromal-to-epithelial signaling in prostate cancer. Cancer research,
65(22):10423–10430, 2005.
86 BIBLIOGRAPHY
[64] Andrew R Joyce and Bernhard Ø Palsson. The model organism as a
system: integrating’omics’ data sets. Nature Reviews Molecular Cell
Biology, 7(3):198–210, 2006.
[65] Cyriac Kandoth, Michael D McLellan, Fabio Vandin, Kai Ye, Beifang
Niu, Charles Lu, Mingchao Xie, Qunyuan Zhang, Joshua F McMichael,
Matthew A Wyczalkowski, et al. Mutational landscape and significance
across 12 major cancer types. Nature, 502(7471):333–339, 2013.
[66] Lavanya Kannan, Marcel Ramos, Angela Re, Nehme El-Hachem,
Zhaleh Safikhani, Deena MA Gendoo, Sean Davis, David Gomez-
Cabrero, Robert Castelo, Kasper D Hansen, et al. Public data and open
source tools for multi-assay genomic investigation of disease. Briefings
in bioinformatics, page bbv080, 2015.
[67] Michael W Kattan, James A Eastham, Alan MF Stapleton, Thomas M
Wheeler, and Peter T Scardino. A preoperative nomogram for disease
recurrence following radical prostatectomy for prostate cancer. Journal
of the National Cancer Institute, 90(10):766–771, 1998.
[68] Tanya Keenan, Beverly Moy, Edmund A Mroz, Kenneth Ross, Andrzej
Niemierko, James W Rocco, Steven Isakoff, Leif W Ellisen, and Aditya
Bardia. Comparison of the genomic landscape between primary breast
cancer in african american versus white women and the association of
racial differences with tumor recurrence. Journal of Clinical Oncology,
33(31):3621–3627, 2015.
[69] Khandan Keyomarsi, Susan L Tucker, Thomas A Buchholz, Matthew
Callister, YE Ding, Gabriel N Hortobagyi, Isabelle Bedrosian, Christo-
pher Knickerbocker, Wendy Toyofuku, Michael Lowe, et al. Cyclin e
and survival in patients with breast cancer. New England Journal of
Medicine, 347(20):1566–1575, 2002.
[70] John R Koza. Genetic programming: on the programming of computers
by means of natural selection, volume 1. MIT press, 1992.
[71] Murray D Krahn, John E Mahoney, Mark H Eckman, John Trachten-
berg, Stephen G Pauker, and Allan S Detsky. Screening for prostate
cancer: a decision analytic view. Jama, 272(10):773–780, 1994.
[72] Alex Krizhevsky, Ilya Sutskever, and Geoffrey E Hinton. Imagenet
classification with deep convolutional neural networks. In Advances in
neural information processing systems, pages 1097–1105, 2012.
BIBLIOGRAPHY 87
[73] Gabriel Kronberger, Stephan Winkler, Michael Affenzeller, Andreas
Beham, and Stefan Wagner. On the success rate of crossover operators
for genetic programming with offspring selection. In International Con-
ference on Computer Aided Systems Theory, pages 793–800. Springer,
2009.
[74] Max Kuhn and Kjell Johnson. Applied predictive modeling, volume 26.
Springer, 2013.
[75] Jacques Lapointe, Chunde Li, John P Higgins, Matt Van De Rijn, Eric
Bair, Kelli Montgomery, Michelle Ferrari, Lars Egevad, Walter Ray-
ford, Ulf Bergerheim, et al. Gene expression profiling identifies clini-
cally relevant subtypes of prostate cancer. Proceedings of the National
Academy of Sciences of the United States of America, 101(3):811–816,
2004.
[76] Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov,
Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart,
Craig H Mermel, Steven A Roberts, et al. Mutational heterogene-
ity in cancer and the search for new cancer-associated genes. Nature,
499(7457):214–218, 2013.
[77] Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders,
A Bapsi Chakravarthy, Yu Shyr, and Jennifer A Pietenpol. Identifi-
cation of human triple-negative breast cancer subtypes and preclinical
models for selection of targeted therapies. The Journal of clinical in-
vestigation, 121(7):2750–2767, 2011.
[78] Benjamin Letham, Cynthia Rudin, Tyler H McCormick, David Madi-
gan, et al. Interpretable classifiers using rules and bayesian analy-
sis: Building a better stroke prediction model. The Annals of Applied
Statistics, 9(3):1350–1371, 2015.
[79] Bo Li and Colin N Dewey. Rsem: accurate transcript quantification
from rna-seq data with or without a reference genome. BMC bioinfor-
matics, 12(1):323, 2011.
[80] Heng Li, Bob Handsaker, Alec Wysoker, Tim Fennell, Jue Ruan,
Nils Homer, Gabor Marth, Goncalo Abecasis, Richard Durbin, et al.
The sequence alignment/map format and samtools. Bioinformatics,
25(16):2078–2079, 2009.
[81] Zachary C Lipton. The mythos of model interpretability. arXiv preprint
arXiv:1606.03490, 2016.
88 BIBLIOGRAPHY
[82] Olvi L Mangasarian, W Nick Street, and William H Wolberg. Breast
cancer diagnosis and prognosis via linear programming. Operations
Research, 43(4):570–577, 1995.
[83] Marilynn Marcione. Prostate testing’s dark side: Men who were
harmed, 2011.
[84] Elke K Markert, Hideaki Mizuno, Alexei Vazquez, and Arnold J
Levine. Molecular classification of prostate cancer using curated ex-
pression signatures. Proceedings of the National Academy of Sciences,
108(52):21276–21281, 2011.
[85] Arvind Singh Mer, Daniel Klevebring, Henrik Gro¨nberg, and Mat-
tias Rantalainen. Study design requirements for rna sequencing-based
breast cancer diagnostics. Scientific reports, 6, 2016.
[86] Craig H Mermel, Steven E Schumacher, Barbara Hill, Matthew L Mey-
erson, Rameen Beroukhim, and Gad Getz. Gistic2.0 facilitates sensitive
and confident localization of the targets of focal somatic copy-number
alteration in human cancers. Genome biology, 12(4):R41, 2011.
[87] Qianxing Mo, Sijian Wang, Venkatraman E Seshan, Adam B Olshen,
Nikolaus Schultz, Chris Sander, R Scott Powers, Marc Ladanyi, and
Ronglai Shen. Pattern discovery and cancer gene identification in in-
tegrated cancer genomic data. Proceedings of the National Academy of
Sciences, 110(11):4245–4250, 2013.
[88] Mehryar Mohri, Afshin Rostamizadeh, and Ameet Talwalkar. Founda-
tions of machine learning. MIT press, 2012.
[89] ABM Moniruzzaman and Syed Akhter Hossain. Nosql database: New
era of databases for big data analytics-classification, characteristics and
comparison. arXiv preprint arXiv:1307.0191, 2013.
[90] Ann Mullally and Jerome Ritz. Beyond hla: the significance of genomic
variation for allogeneic hematopoietic stem cell transplantation. Blood,
109(4):1355–1362, 2007.
[91] Naomi Nakayama, Kentaro Nakayama, Yeasmin Shamima, Masako
Ishikawa, Atsuko Katagiri, Kouji Iida, and Khoji Miyazaki. Gene am-
plification ccne1 is related to poor survival and potential therapeutic
target in ovarian cancer. Cancer, 116(11):2621–2634, 2010.
BIBLIOGRAPHY 89
[92] Cancer Genome Atlas Network et al. Comprehensive molecular por-
traits of human breast tumors. Nature, 490(7418):61, 2012.
[93] Cancer Genome Atlas Research Network et al. The molecular taxonomy
of primary prostate cancer. Cell, 163(4):1011–1025, 2015.
[94] William D Orsi, Virginia P Edgcomb, Glenn D Christman, and Jen-
nifer F Biddle. Gene expression in the deep biosphere. Nature,
499(7457):205–208, 2013.
[95] J Guillermo Paez, Pasi A Ja¨nne, Jeffrey C Lee, Sean Tracy, Heidi
Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Linde-
man, Titus J Boggon, et al. Egfr mutations in lung cancer: correlation
with clinical response to gefitinib therapy. Science, 304(5676):1497–
1500, 2004.
[96] Joel S Parker, Michael Mullins, Maggie CU Cheang, Samuel Leung,
David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiap-
ing He, Zhiyuan Hu, et al. Supervised risk predictor of breast cancer
based on intrinsic subtypes. Journal of clinical oncology, 27(8):1160–
1167, 2009.
[97] Sven Perner, Francesca Demichelis, Rameen Beroukhim, Folke H
Schmidt, Juan-Miguel Mosquera, Sunita Setlur, Joelle Tchinda,
Scott A Tomlins, Matthias D Hofer, Kenneth G Pienta, et al. Tmprss2:
Erg fusion-associated deletions provide insight into the heterogeneity
of prostate cancer. Cancer research, 66(17):8337–8341, 2006.
[98] Charles M Perou, Stefanie S Jeffrey, Matt Van De Rijn, Christian A
Rees, Michael B Eisen, Douglas T Ross, Alexander Pergamenschikov,
Cheryl F Williams, Shirley X Zhu, Jeffrey CF Lee, et al. Distinctive
gene expression patterns in human mammary epithelial cells and breast
cancers. Proceedings of the National Academy of Sciences, 96(16):9212–
9217, 1999.
[99] Charles M Perou, Stefanie S Jeffrey, Matt Van De Rijn, Christian A
Rees, Michael B Eisen, Douglas T Ross, Alexander Pergamenschikov,
Cheryl F Williams, Shirley X Zhu, Jeffrey CF Lee, et al. Distinctive
gene expression patterns in human mammary epithelial cells and breast
cancers. Proceedings of the National Academy of Sciences, 96(16):9212–
9217, 1999.
[100] Charles M Perou, Therese Sørlie, Michael B Eisen, Matt van de Rijn,
Stefanie S Jeffrey, Christian A Rees, Jonathan R Pollack, Douglas T
90 BIBLIOGRAPHY
Ross, Hilde Johnsen, Lars A Akslen, et al. Molecular portraits of
human breast tumours. Nature, 406(6797):747–752, 2000.
[101] Dorothee Pflueger, Ste´phane Terry, Andrea Sboner, Lukas Habegger,
Raquel Esgueva, Pei-Chun Lin, Maria A Svensson, Naoki Kitabayashi,
Benjamin J Moss, Theresa Y MacDonald, et al. Discovery of non-
ets gene fusions in human prostate cancer using next-generation rna
sequencing. Genome research, 21(1):56–67, 2011.
[102] Riccardo Poli and William B Langdon. On the search properties of
different crossover operators in genetic programming. Genetic Pro-
gramming, pages 293–301, 1998.
[103] J. Ross Quinlan. Simplifying decision trees. International journal of
man-machine studies, 27(3):221–234, 1987.
[104] J Ross Quinlan. C4. 5: programs for machine learning. Elsevier, 2014.
[105] R Core Team. R: A Language and Environment for Statistical Comput-
ing. R Foundation for Statistical Computing, Vienna, Austria, 2016.
[106] Ronald L Rivest. Learning decision lists. Machine learning, 2(3):229–
246, 1987.
[107] Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz,
Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-
Ellen Taplin, Colin C Pritchard, Gerhardt Attard, et al. Integrative
clinical genomics of advanced prostate cancer. Cell, 161(5):1215–1228,
2015.
[108] Hege G Russnes, Nicholas Navin, James Hicks, and Anne-Lise
Borresen-Dale. Insight into the heterogeneity of breast cancer through
next-generation sequencing. The Journal of clinical investigation,
121(10):3810–3818, 2011.
[109] Mehmet Kemal Samur. Rtcgatoolbox: a new tool for exporting tcga
firehose data. PloS one, 9(9):e106397, 2014.
[110] Valerie Schneider and Deanna Church. Genome reference consortium.
2013.
[111] Sarit Schwartz, John Wongvipat, Cath B Trigwell, Urs Hancox, Brett S
Carver, Vanessa Rodrik-Outmezguine, Marie Will, Paige Yellen, Elisa
BIBLIOGRAPHY 91
de Stanchina, Jose´ Baselga, et al. Feedback suppression of pi3kα signal-
ing in pten-mutated tumors is relieved by selective inhibition of pi3kβ.
Cancer cell, 27(1):109–122, 2015.
[112] Muhammad Shaheen, Muhammad Shahbaz, and Aziz Guergachi. Con-
text based positive and negative spatio-temporal association rule min-
ing. Knowledge-Based Systems, 37:261–273, 2013.
[113] Michael M Shen and Cory Abate-Shen. Molecular genetics of prostate
cancer: new prospects for old challenges. Genes & development,
24(18):1967–2000, 2010.
[114] Ronglai Shen, Adam B Olshen, and Marc Ladanyi. Integrative cluster-
ing of multiple genomic data types using a joint latent variable model
with application to breast and lung cancer subtype analysis. Bioinfor-
matics, 25(22):2906–2912, 2009.
[115] Rebecca Siegel, Deepa Naishadham, and Ahmedin Jemal. Cancer
statistics, 2013. CA: a cancer journal for clinicians, 63(1):11–30, 2013.
[116] Rebecca L Siegel, Kimberly D Miller, and Ahmedin Jemal. Cancer
statistics, 2016. CA: a cancer journal for clinicians, 66(1):7–30, 2016.
[117] Dennis J Slamon, Brian Leyland-Jones, Steven Shak, Hank Fuchs, Vir-
ginia Paton, Alex Bajamonde, Thomas Fleming, Wolfgang Eiermann,
Janet Wolter, Mark Pegram, et al. Use of chemotherapy plus a mon-
oclonal antibody against her2 for metastatic breast cancer that over-
expresses her2. New England Journal of Medicine, 344(11):783–792,
2001.
[118] DJ Slamon. Human breast cancer: correlation of relapse and. Science,
3798106(177):235, 1987.
[119] Gordon K Smyth et al. Linear models and empirical bayes methods for
assessing differential expression in microarray experiments. Stat Appl
Genet Mol Biol, 3(1):3, 2004.
[120] NATIONAL AUDUBON SOCIETY. The audubon society field guide
to north american mushrooms. alfred a, 1981.
[121] Lincoln D Stein. Integrating biological databases. Nature Reviews
Genetics, 4(5):337–345, 2003.
92 BIBLIOGRAPHY
[122] W Nick Street, William H Wolberg, and Olvi L Mangasarian. Nuclear
feature extraction for breast tumor diagnosis. In IS&T/SPIE’s Sympo-
sium on Electronic Imaging: Science and Technology, pages 861–870.
International Society for Optics and Photonics, 1993.
[123] MH Eileen Tan, Jun Li, H Eric Xu, Karsten Melcher, and Eu-leong
Yong. Androgen receptor: structure, role in prostate cancer and drug
discovery. Acta Pharmacologica Sinica, 36(1):3–23, 2015.
[124] Joseph H Taube, Jason I Herschkowitz, Kakajan Komurov, Alicia Y
Zhou, Supriya Gupta, Jing Yang, Kimberly Hartwell, Tamer T Onder,
Piyush B Gupta, Kurt W Evans, et al. Core epithelial-to-mesenchymal
transition interactome gene-expression signature is associated with
claudin-low and metaplastic breast cancer subtypes. Proceedings of
the National Academy of Sciences, 107(35):15449–15454, 2010.
[125] Barry S Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha
Gopalan, Yonghong Xiao, Brett S Carver, Vivek K Arora, Poorvi
Kaushik, Ethan Cerami, Boris Reva, et al. Integrative genomic profil-
ing of human prostate cancer. Cancer cell, 18(1):11–22, 2010.
[126] AR Thorner, Katherine A Hoadley, JS Parker, S Winkel, RC Millikan,
and Charles M Perou. In vitro and in vivo analysis of b-myb in basal-
like breast cancer. Oncogene, 28(5):742–751, 2009.
[127] Scott A Tomlins, Mohammed Alshalalfa, Elai Davicioni, Nicholas
Erho, Kasra Yousefi, Shuang Zhao, Zaid Haddad, Robert B Den,
Adam P Dicker, Bruce J Trock, et al. Characterization of 1577 primary
prostate cancers reveals novel biological and clinicopathologic insights
into molecular subtypes. European urology, 68(4):555–567, 2015.
[128] Scott A Tomlins, Bharathi Laxman, Saravana M Dhanasekaran, Beth E
Helgeson, Xuhong Cao, David S Morris, Anjana Menon, Xiaojun Jing,
Qi Cao, Bo Han, et al. Distinct classes of chromosomal rearrange-
ments create oncogenic ets gene fusions in prostate cancer. Nature,
448(7153):595–599, 2007.
[129] Scott A Tomlins, Daniel R Rhodes, Sven Perner, Saravana M
Dhanasekaran, Rohit Mehra, Xiao-Wei Sun, Sooryanarayana Varam-
bally, Xuhong Cao, Joelle Tchinda, Rainer Kuefer, et al. Recurrent
fusion of tmprss2 and ets transcription factor genes in prostate cancer.
science, 310(5748):644–648, 2005.
BIBLIOGRAPHY 93
[130] William N Venables and Brian D Ripley. Modern applied statistics with
S-PLUS. Springer Science & Business Media, 2013.
[131] Ying-Wooi Wan, Genevera I Allen, and Zhandong Liu. Tcga2stat:
simple tcga data access for integrated statistical analysis in r. Bioin-
formatics, page btv677, 2015.
[132] Fulton Wang and Cynthia Rudin. Causal falling rule lists. arXiv
preprint arXiv:1510.05189, 2015.
[133] Xiao-Song Wang, Sunita Shankar, Saravana M Dhanasekaran, Bushra
Ateeq, Atsuo T Sasaki, Xiaojun Jing, Daniel Robinson, Qi Cao, John R
Prensner, Anastasia K Yocum, et al. Characterization of kras rear-
rangements in metastatic prostate cancer. Cancer discovery, 1(1):35–
43, 2011.
[134] John N Weinstein, Eric A Collisson, Gordon B Mills, Kenna R Mills
Shaw, Brad A Ozenberger, Kyle Ellrott, Ilya Shmulevich, Chris Sander,
Joshua M Stuart, Cancer Genome Atlas Research Network, et al. The
cancer genome atlas pan-cancer analysis project. Nature genetics,
45(10):1113–1120, 2013.
[135] Rick Weiss. Nih launches cancer genome project. Washington Post,
2005.
[136] Hadley Wickham. ggplot2: Elegant Graphics for Data Analysis.
Springer-Verlag New York, 2009.
[137] Marvin N Wright and Andreas Ziegler. ranger: A fast implementation
of random forests for high dimensional data in c++ and r. arXiv
preprint arXiv:1508.04409, 2015.
[138] Stefan Wrobel. An algorithm for multi-relational discovery of sub-
groups. In European Symposium on Principles of Data Mining and
Knowledge Discovery, pages 78–87. Springer, 1997.
[139] Hongyu Yang, Cynthia Rudin, and Margo Seltzer. Scalable bayesian
rule lists. arXiv preprint arXiv:1602.08610, 2016.
[140] Sungyong You, Beatrice S Knudsen, Nicholas Erho, Mohammed Alsha-
lalfa, Mandeep Takhar, Hussam Al-deen Ashab, Elai Davicioni, R Jef-
frey Karnes, Eric A Klein, Robert B Den, et al. Integrated classification
of prostate cancer reveals a novel luminal subtype with poor outcome.
Cancer Research, 76(17):4948–4958, 2016.
94 BIBLIOGRAPHY
[141] Min Yu, Aditya Bardia, Ben S Wittner, Shannon L Stott, Malgorzata E
Smas, David T Ting, Steven J Isakoff, Jordan C Ciciliano, Marissa N
Wells, Ajay M Shah, et al. Circulating breast tumor cells exhibit dy-
namic changes in epithelial and mesenchymal composition. science,
339(6119):580–584, 2013.
[142] Mohammed Javeed Zaki. Scalable algorithms for association mining.
IEEE Transactions on Knowledge and Data Engineering, 12(3):372–
390, 2000.
[143] Mehdi Zarrei, Jeffrey R MacDonald, Daniele Merico, and Stephen W
Scherer. A copy number variation map of the human genome. Nature
Reviews Genetics, 16(3):172–183, 2015.
[144] Zhenhuan Zhang, Hiroko Yamashita, Tatsuya Toyama, Hiroshi Sug-
iura, Yoshiaki Ando, Keiko Mita, Maho Hamaguchi, Yasuo Hara,
Shunzo Kobayashi, and Hirotaka Iwase. Ncor1 mrna is an independent
prognostic factor for breast cancer. Cancer letters, 237(1):123–129,
2006.
[145] Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, Akira Sakurada,
Jean-Claude Cutz, Ni Liu, Tong Zhang, Paula Marrano, Marlo White-
head, Jeremy A Squire, et al. Role of kras and egfr as biomarkers of
response to erlotinib in national cancer institute of canada clinical tri-
als group study br. 21. Journal of clinical oncology, 26(26):4268–4275,
2008.
[146] Yitan Zhu, Peng Qiu, and Yuan Ji. Tcga-assembler: open-source
software for retrieving and processing tcga data. Nature methods,
11(6):599–600, 2014.
Abbreviations
AKT1 AKT Serine/Threonine Kinase 1. 91
APC APC, WNT Signaling Pathway Regulator. 92, 93
API application programming interface. 18, 20–24, 67, 68, 83, 84, Glossary:
API
AR Androgen Receptor. 3, 62, 64, 72, 73, 75, 92
ATM ATM Serine/Threonine Kinase. 92, 93
bagging Bootstrap Aggregation. 33, 35, Glossary: Boostrap Aggregation
bp base pairs. 16, 86, Glossary: bp
BRAF B-Raf Proto-Oncogene, Serine/Threonine Kinase. 91, 93
BRCA1 BRCA1, DNA Repair Associated. 91, 92
BRCA2 BRCA2, DNA Repair Associated. 91, 92
BRL Bayesian Rule List. 69, 70
CCNB1 Cyclin B1. 7, 58, 70, 75
CCND1 Cyclin D1. 93
CCNE1 Cyclin E1. 59
CDK12 Cyclin Dependent Kinase 12. 92
CDKN1B Cyclin Dependent Kinase Inhibitor 1B. 91, 92
CDKN2A Cyclin Dependent Kinase Inhibitor 2A. 92, 93
CHD1 Chromodomain Helicase DNA Binding Protein 1. 91, 92
95
96 Abbreviations
CI confidence interval. 37, 89, Glossary: confidence intervals
CNV Copy Number Variation. 7, 10, 16, 17, 25, 51, 53, 55, 56, 58, 61, 64,
71, 72, Glossary: CNV
CRAN Comprehensive R Archive Network. Glossary: CRAN
CSV Comma Separated Values. 21, Glossary: CSV
CTNNB1 Catenin Beta 1. 91
DBMS Database Management System. 21, Glossary: DBMS
DNA deoxyribonucleic acid. 10, 15, 83, 86, Glossary: DNA
EDL evolutionary decision list. 3, 8, 13, 30, 38, 43, 44, 48, 50, 53, 56, 60–62,
64, 69–73, 75, Glossary: EDL
EGFR Epidermal Growth Factor Receptor. 51, 54
EMT epithelial-to-mesenchymal transition. 58, 59, Glossary: epithelial-to-
mesenchymal transition
ERB2 Erb-B2 Receptor Tyrosine Kinase 2. 7, 34, 58, 71, 75
ERF ETS2 Repressor Factor. 93
ERG ERG, ETS Transcription Factor. 10, 17, 64, 72, 90
ESR1 Estrogen Receptor 1. 7, 58, 70, 71, 75
ETS ETS transcription factor family. 64, 72, Glossary: ETS transcription
factor family
ETV1 ETS Variant 1. 17, 64, 90
ETV4 ETS Variant 4. 90
FAM175A Family With Sequence Similarity 175 Member A. 92
FANCC Fanconi Anemia Complementation Group C. 92, 93
FANCD2 Fanconi Anemia Complementation Group D2. 92
FGFR1 Fibroblast Growth Factor Receptor 1. 53, 55
FLI1 Fli-1 Proto-Oncogene, ETS Transcription Factor. 90
Abbreviations 97
FN false negatives. 40, Glossary: false negatives
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TN true negatives. 40, Glossary: true negatives
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TSHZ3 Teashirt Zinc Finger Homeobox 3. 51, 52
TTF1 Transcription Termination Factor 1. 51, 54
URL Uniform Resource Locator. 21, 22, Glossary: URL
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alignment An alignment (or sequence alignment) is the process of arranging
two sequences to each other. Often short reads are aligned to a reference
genome. 15
API An API is a set of definitions, allowing the automated interaction be-
tween two systems. 18
backward elimination A set of 50 genes, by which expression status a
cancer subtypes can be determined. 7
boosting A meta algorithm to build a strong classifier from several weak
ones. 35
Boostrap Aggregation A technique used by machine learning models to
increase stability and accuracy. n′ samples are drawn from n with
replacement, a model is build using n′ samples. This procedure is
repeated k times.. 33
bp A base pair consists out of two nucleobases, bound to each other. They
form the building blocks of DNA double helix. 16
branch A container within the git version control system. Often one master
branch serving the software product and several branches for develop-
ment exist. 23
C++ A programming language, allowing more efficient computations than
R. 13
cardinality The number of unique elements in a set. The cardinality of
S = a, a, b, c would be 3, as there are 3 unique elements. 26, 31, 36, 39,
44
cBioPortal A portal to provide visualization, analysis and download of
large-scale cancer genomics data sets. v, 18–20, 61, 68
101
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CNV The number of gene copies in a genome, differing from two. 7
confidence intervals An interval yielding the precision of an estimated pa-
rameter. 37
confusion matrix A matrix indication the number of false and correct pre-
dicted samples, compared to their true label. 40
cron-job A small script which is run by a pre-defined interval. 23
CSV A file type, where information is stored in comma separated columns.
21
DBMS A system to manage multiple databases of the same type. 21
DNA A molecule that carries instructions for reproduction, growth and
development all living organisms. 10
EDL An EDL builds a statistical classifier by the means of evolutionar com-
puting. 3
ensemble method A machine learning method, which utilizes multiple mod-
els to perform a classification or regression task. 32
epithelial-to-mesenchymal transition A process in which cells lose their
cell polarity and cell-cell adhesion, allowing them to become mesenchy-
mal stem cells. 58
ETS transcription factor family Also known as E26 transformation-specific
is a family genes, known to be associated with leukemia and several
cancer disease. 64
expected accuracy The accuracy any random classifier is expected to achieve.
41
false negatives The number of positive samples being predicted negative.
40
false positives The number of negative samples being predicted positive.
40
Firebrowse A tool on top of the Firehose Pipeline to provide online access
to analytical results over an API. 3, 18, 20–23, 68, 85
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FirebrowseR A client to the Firebrowse software, enabling automatic data
integration into the R environment. 3, 20, 23–25, 43, 51, 53–55, 61, 67,
75
Firehose Pipeline A data portal to systematize the analyses of TCGA
data sets. 18–21, 23, 51, 53, 55, 56, 67, 68, 84
gene fusion The event that a new gene is formed from two previously sep-
arated genes. 17
genotype Set of amino acids to be translated into an organism phenotype.
15, 17, 85
gini index A measure for the impurity of a set. 31, 32
grid search A method used for parameter optimization. For two parame-
ters, the two vectors x and y, containing the parameters to test, span
a grid. This results in x ∗ y models which need to be evaluated. 43
HTTP A protocol used for machine-machine communication, commonly
used in the world wide web. 21
inter-rater reliability The degree of agreement among two raters. 14
JSON A compact and human readable file format, created for data exchange
between applications. 21
label The variable to predict in a classification task. Also referred to as y
in formulas. 14, 15
MAP A Bayesian parameters estimator, based on the a-priori distribution.
31
NGS A modern and efficient way to determine the order of nucleotides,
compared to Sanger sequencing. 15
noSQL A database which is not structured as an Structured Query Lan-
guage (SQL) database, mostly key/value stores. 17
pda A pushdown automaton is a deterministic automaton, with an addi-
tional stack. 36
phenotype Set of characteristics the genotype is expressed into. 17, 85
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predictor A samples attribute, used in the context of classification prob-
lems. 14
Principal component analysis A PCA creates a set of uncorrelated vari-
ables from a set of correlated variables. 30
R A statistical computing environment, used for calculations and plotting.
13
Rcpp An extension to the R programming language, to execute C++ code
within the R environment. 13
reads Short fragments (50-200 bp) of the amino acid sequence. 15
REST A programming paradigm for distributed systems, enabling the inter-
machine communication over a set pre-defined commands. 20
RNA Similar to DNA, but single stranded. 17
RPKM A method of quantifying gene expression from RNA sequencing
data by normalizing for total read length and the number of sequencing
reads. 25
RSEM A software package for estimating gene and isoform expression levels
from RNA sequencing data. 25
rule support The percentage of samples covert by a rule. 36, 44
SAM A file format to store reads mapped to a reference in. 21
Sanger sequencing The first known method to determine the nucleotides
order in a DNA molecule. 85
SNP The variation of a single base pair in read, which occurs in >1% of all
samples within a population. 10
SQL A standardized language to work with databases. 85
standard deviation A measure indicating the amount of variation within
a set of values. 5
SVM A kernel based machine learning model. 30
TCGA A data portal run by the National Institute of Health (NIH), to
provide public genomic data sets. 3, 19, 23, 85
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transcript A transcript is a segment of a gene, which is translated by a
single RNA. 17
translation The process of translating a genes amino acid sequence in a
protein. 15
true negatives The number of false labels being predicted as negative. 40
true positives The number of true labels being predicted as true. 37
unit tests Requirements to programmed functions, which need to be ful-
filled before the software product can be finalized. 23
URL An unique identifier locate an resource on the network. 21
VCF A file format used store mutation data. 21
Web-TCGA An online platform to visualize and analyze genomic data sets
provided by the TCGA and Firehose Pipeline. 3, 21, 23, 25, 43, 51,
53–55, 75
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Appendix A
Appendix
A.1 Test Data Decision List
In this section decision lists for each test data set (described in 3.2 and 4.1),
generated over all test samples, are given. Trailing numbers indicate the
rules precision and their CI in braces.
A.1.1 The Tic Tac Toe Decision List
IF V2=x V1=x V3=x THEN win 1 (0.95 - 1)
ELSE IF V8=x V7=x V9=x THEN win 1 (0.95 - 1)
ELSE IF V9=x V5=x V1=x THEN win 1 (0.96 - 1)
ELSE IF V6=x V5=x V4=x THEN win 1 (0.95 - 1)
ELSE IF V4=x V1=x V7=x THEN win 1 (0.95 - 1)
ELSE IF V8=x V5=x V2=x THEN win 1 (0.95 - 1)
ELSE IF V6=x V3=x V9=x THEN win 1 (0.95 - 1)
ELSE IF V7=x V5=x V3=x THEN win 1 (0.96 - 1)
ELSE loss
A.1.2 The Titanic Decision List
IF class = Third THEN survival=No 0.75 (0.71 - 0.78)
IF gender=Female & age=Adult THEN survial=Yes 0.92 (0.88 - 0.95)
IF age=Child THEN survival=Yes 1 (0.88 - 1)
ELSE No
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A.1.3 The Mushrooms Decision List
IF odor=none & bruises=no & stalk-surface-above-ring=smooth THEN edible 1 (1 - 1)
ELSE IF gill-size=narrow & gill-attachment=free & gill-spacing=close THEN poisonous 1 (1 - 1)
ELSE IF odor=foul & veil-color=white THEN poisonous 1 (1 - 1)
ELSE IF stalk-shape=enlargingenlarging & population=several THEN poisonous 1 (0.63 - 1)
ELSE IF gill-size=narrow & bruises=no THEN poisonous 1 (0.97 - 1)
ELSE IF gill-color=white & odor=no THEN edible 1 (0.99 - 1)
ELSE IF habitat=woods & bruises=nof veil-color=white THEN poisonous 1 (0.95 - 1)
ELSE IF stalk-surface-above-ring=fibrous & gill-attachment=free THEN edible 1 (0.9 - 1)
ELSE edible
A.1.4 The Cars Database decision lists
IF maint=low & safety=low THEN unacc 1 (0.97 - 1)
ELSE IF persons=2 THEN unacc 1 (0.99 - 1)
ELSE IF lug-boot=med & persons=2 THEN unacc 0 (0 - 0)
ELSE IF maint=vhigh & buying=high THEN unacc 1 (0.95 - 1)
ELSE IF buying=low & maint=low good 0.48 (0.33 - 0.63)
ELSE IF safety=med & buying=low THEN acc 0.64 (0.52 - 0.75)
ELSE IF maint=low & buying=med good 0.48 (0.33 - 0.63)
ELSE IF maint=high & buying=vhigh THEN unacc 1 (0.95 - 1)
ELSE IF safety=low THEN unacc 1 (0.98 - 1)
ELSE IF doors=2 & lug-boot=small THEN unacc 0.71 (0.55 - 0.84)
ELSE IF maint=vhigh & persons=2 THEN unacc 0 (0 - 0)
ELSE IF maint=vhigh & buying=vhigh THEN unacc 1 (0.92 - 1)
ELSE IF safety=high & maint=vhigh THEN acc 1 (0.92 - 1)
ELSE IF safety=high & lug-boot=small THEN acc 0.89 (0.77 - 0.96)
ELSE IF safety=high & buying=high THEN acc 1 (0.93 - 1)
ELSE IF buying=med & maint=med THEN acc 0.66 (0.49 - 0.8)
ELSE IF buying=low vgood 0.81 (0.64 - 0.93)
ELSE IF lug-boot=small THEN unacc 1 (0.92 - 1)
ELSE IF buying=low & safety=high THEN unacc 0 (0 - 0)
ELSE IF doors=4 & safety=low THEN unacc 0 (0 - 0)
ELSE IF safety=high & persons=4 THEN acc 1 (0.86 - 1)
ELSE IF safety=med & lug-boot=big THEN acc 1 (0.94 - 1)
ELSE IF doors=2 & safety=med THEN unacc 1 (0.77 - 1)
ELSE IF buying=low & maint=high THEN unacc 0 (0 - 1)
ELSE IF doors=3 & persons=4 THEN unacc 1 (0.59 - 1)
ELSE THEN acc
A.2 Common Altered Genes in Prostate Can-
cer
In the following the preselected features for the prostate cancer classification
task are listed. Frequently occurring gene fusions, somatic mutations and
copy number alterations for primary, as well as for mCRPC patients are
taken into account. The lists are based on publications from Perner et al
[97], Cooper et al [23], Pflueger et al [101], Tomlins et al [128], Taylor et al
[125] and Wang et al [133].
• ERG
• ETV1
• ETS Variant 4 (ETV4 )
• Fli-1 Proto-Oncogene, ETS Transcription Factor (FLI1 )
• PIK3CA
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• PIK3CB
• Phosphoinositide-3-Kinase Regulatory Subunit 1 (PIK3R1 )
• SPOP
• FOXA1
• Mediator Complex Subunit 12 (MED12 )
• Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic (IDH1 )
• Lysine Methyltransferase 2A (KMT2A)
• Lysine Methyltransferase 2A (KMT2C )
• Lysine Methyltransferase 2D (KMT2D)
• Lysine Demethylase 6A (KDM6A)
• SET Domain Containing 2 (SETD2 )
• Chromodomain Helicase DNA Binding Protein 1 (CHD1 )
• TP53
• PTEN
• PIK3CA
• PIK3CB
• PIK3R1
• B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF )
• HRas Proto-Oncogene, GTPase (HRAS )
• Catenin Beta 1 (CTNNB1 )
• AKT Serine/Threonine Kinase 1 (AKT1 )
• BRCA1, DNA Repair Associated (BRCA1 )
• BRCA2, DNA Repair Associated (BRCA2 )
• Cyclin Dependent Kinase Inhibitor 1B (CDKN1B)
• (RAF1 )
110 APPENDIX A. APPENDIX
• APC, WNT Signaling Pathway Regulator (APC )
• RB Transcriptional Corepressor 1 (RB1 )
• Zinc Finger MYM-Type Containing 3 (ZMYM3 )
• ATM Serine/Threonine Kinase (ATM )
• Cyclin Dependent Kinase 12 (CDK12 )
• Fanconi Anemia Complementation Group C (FANCC )
• Fanconi Anemia Complementation Group D2 (FANCD2 )
• AR
• NCOR1
• Nuclear Receptor Corepressor 1 (NCOR2 )
• MutL Homolog 1 (MLH1 )
• MutS Homolog 2 (MSH2 )
• Cyclin Dependent Kinase Inhibitor 2A (CDKN2A)
• KMT2C
• ZFHX3
• PTEN
• TP53
• CHD1
• BRCA1
• BRCA2
• CDKN1B
• RB1
• CDK12
• FANCD2
• Family With Sequence Similarity 175 Member A (FAM175A)
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• FANCC
• RAD51 Paralog C (RAD51C )
• Speckle Type BTB/POZ Protein Like (SPOPL)
• (ZBTB16 )
• NCOR1
• NCOR2
• PIK3R1
• BRAF
• RAF1
• APC
• ATM
• MLH1
• MSH2
• CDKN2A
• Cyclin D1 (CCND1 )
• ZFHX3
• GNAS Complex Locus (GNAS )
• ETS2 Repressor Factor (ERF )
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